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Abstract 
 
Background: Patients with cardiovascular disease (CVD) have a two-fold increased risk 
of depression as compared to patients without CVD. According to the American Heart 
Association (AHA, 2016), there is no gold-standard procedure for screening for 
depression in cardiovascular patients. Screening for depression varies greatly across 
specialties and practices, often leaving a gap for detection and treatment of depression in 
cardiac patients. There are many depression screening tools available; however, the AHA 
recommends use of the patient health questionnaire (PHQ) screening tool. The PHQ-2 
and PHQ-9 questionnaires are the most brief, sensitive, and specific depression screening 
tool for patients with cardiovascular disease.  
Method: A quality improvement study was designed and implemented to determine the 
usability of the PHQ screening tool in primary care and to compare the results of the 
screening tools between practices. A descriptive pre-test and post-test survey design was 
conducted to compare findings from two primary care settings, which utilized the PHQ 
depression screening tool to screen for depression in cardiovascular patients. A total of 60 
charts were audited, 30 charts from each practice. A retrospective chart review was 
conducted at completion of the study in order to compare the results of depression 
screenings and implemented treatments between the two practices. 
Results: Of the 60 audited charts, 51 patients were screened for depression by their 
primary care provider. After frequency distributions were calculated, it was noted that
vi 
 
29% of the sample population had depressive symptoms. This data is consistent with the 
evidence-based literature that demonstrates that patients with cardiovascular disease are 
at high risk for depression and should be routinely screened for depression in their 
primary care homes as recommended by the American Heart Association (2016). Each of 
these patients (n=15) who screened positive for depression was started on treatment for 
depression at the time of the initial depression screening visit. 
Implications: Findings from the quality improvement project underscored the need for 
primary care providers to utilize the PHQ screening tool as the standard for screening in 
patients with CVD due to the incidence of depression in cardiovascular patients and the 
tool’s efficacy and ease of use. Depression screening in primary care should be included 
in continuing medical education requirements for providers working in the primary care 
setting. It is important to support all levels of government to adopt mental health policies 
and to integrate mental health policy into public health policy and general social policy. 
Additional research is needed to properly characterize evidence-based care of patients 
with comorbid depression and cardiovascular disease. 
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Chapter 1 Introduction 
1.1 Description of the Clinical Problem 
In patients with cardiovascular disease (CVD) seen in primary care, data suggests 
a high prevalence rate for depression with several studies indicating that approximately 
15-20% of patients who have had a myocardial infarction (MI) meet criteria for major 
depressive disorder (Lichtman, Bigger, Blumenthal, and Frasure-Smith, 2008). An even 
higher percentage of patients with CVD display an elevated level of depressive symptoms 
that would meet criteria for other depressive disorders (Lichtman, et al., 2008).  
According to Lichtman, et al., (2008), depression is frequently found in patients with 
coronary heart disease (CHD) and is also independently associated with an increase in 
cardiovascular morbidity and mortality (p. 1768).  Among these patients, however, 
depression is often underdiagnosed or misdiagnosed due to the patients’ other 
comorbidities and the lack of standardized depression screening tools (McGuire, Ahearn, 
and Doering, 2015). 
Numerous studies have identified a significant correlation between depression, 
increased risk of cardiovascular disease, and poor quality of life (Peters, Pinto, Beckett, 
Swift, Potter, McCormack,…& Bulpitt, 2010; McGuire, et al., 2015; Mavrides & 
Nemeroff, 2013). As Lichtman et al., (2008) discusses, “depression reduces the chances 
of successful modifications of other cardiac risk factors and participation in cardiac 
rehabilitation and is associated with higher healthcare utilization and costs and, not  
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surprisingly, greatly reduced quality of life” (p. 1769). Depression is also 
associated with a poorer prognosis for patients with cardiovascular disease (Peters, et al., 
2010).  
McGuire, et al., (2015) suggests that there is a need for more research in 
depression and cardiac patients due to costs, co-morbidities, and outcomes.  Recently, the 
American Heart Association assembled recommendations for primary care providers to 
screen CVD patients for depression (Mavrides & Nemeroff, 2013).  The purpose of this 
study is to determine the best screening depression tool and implement the tool for early 
detection of depression in primary care settings for patients with cardiovascular disease 
1.2 Scope of the Clinical Problem 
Patients with cardiovascular disease have a two-fold increased risk of depression 
as compared to patients without heart disease (Kronish, Krupka, & Davidson, 2012, p. 
126). Similarly, Lichtman et al., (2008) also discusses that depression is approximately 
three times more common in patients after they have had an acute myocardial infarction 
(AMI) as compared to the general population (p. 1768).  
In terms of cost, it is estimated that the economic impact of depression in the 
United States ranges from a devastating $20 billion to $45 billion annually, rivaling the 
costs of chronic diseases such as hypertension (Rutledge, Vaccarino, Johnson, Bittner, 
Olson, Linke,…Shaw, 2009). Even minor depression has been shown to increase 
economic burden (Rutledge et al., 2009). According to Rutledge, et al., (2009), 
depression is associated with a 15% to 53% increase in 5-year cardiovascular costs. 
These costs have been described as direct and indirect. Direct costs include 
hospitalizations, office visits, procedures, and medications; whereas, indirect costs 
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include out-of-pocket expenses, lost productivity and wages, and travel (Rutledge, et al., 
2009, p. 176). 
In terms of health comorbidities, CVD and Depression are both highly prevalent, 
coexisting diseases (Paz-Filho, Licinio, & Wong, 2010). They share common 
pathophysiological etiologies or co-morbidities, such as cardiac rhythm disturbances 
alterations in the hypothalamic-pituitary axis, and hemorheologic, inflammatory and 
serotoninergic changes (Paz-Filho, 2010). There is compelling evidence that depression is 
an independent risk factor for both the development of CVD and for worsening prognosis 
once CVD is established (Paz-Filho, 2010). Evidence has also shown that patients with 
CVD may become depressed as a response to the burden of a co-morbid condition (Paz-
Filho, 2010). 
In addition to the co-morbidity correlation between CVD and Depression, there is 
strong evidence to suggest that depression is associated with an increased risk of 
cardiovascular disease and cardiac death (Glassman, 2007). Patients with depression and 
comorbid CVD have a higher mortality rate than the general population (Hare, Toukhsati, 
Johansson, & Jaarsma, 2014). Evidence has shown a severity relationship between 
depression and CVD: the more severe the depression, the higher the subsequent risk of 
mortality and other cardiovascular events (Hare et al., 2014). Furthermore, short-term 
prognosis is found between these co-morbidities (Jiang, Alexander, Christopher, 
Kuchibhatla, Gaulden, Cuffe,…O’Connor, 2001). 
For psychosocial effects of CVD and depression, evidence suggests that 
dysfunctional personal relationships or family responsibilities are correlated for elevated 
CVD risk (Low, Thurston, & Matthews, 2010). Supportive social relationships and 
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positive psychological factors are associated with reduced risk of depression in patients 
with CVD, as well as reduced risk of morbidity and mortality associated with CVD (Low, 
et al., 2010). Consideration of psychosocial factors may improve the identification of 
patients at elevated risk for CVD and depression, and may also lead to the development 
of effective psychological interventions for patients with or at risk for CVD (Low, et al., 
2010).  Moreover, evidence suggests that social and family support play important roles 
in CVD and mental health (Healthy People 2020).  In other words, stress related to 
interpersonal relationships and family responsibilities has been shown to be an important 
risk factor in the development of CVD (Low, et al., 2010).  
Decreased sexual activity and sexual dysfunction are common in patients with 
CVD and can increase depression (Armstrong, 2012). Changes in sexual activity after a 
cardiac event may impair a patient’s quality of life and may negatively affect 
psychological health (Armstrong, 2012). The resulting anxiety and depression may be an 
important contributing cause of sexual dysfunction, including decreased libido, difficulty 
with arousal and orgasm, and dyspareunia (Armstrong, 2012). 
Finally, hospital readmission rates and depression are common.  Data show that 
patients with major depression and cardiovascular disease have increased readmissions 
and lengthier hospital stays (Jiang, et al., 2001). In one study, patients with CHF who had 
major depression were more than twice as likely as non-depressed patients to die or be 
readmitted within 3 months to 1 year after hospitalization (Jiang, et al., 2001). 
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1.3 Analysis of Current Practice 
According to McGuire et al., (2015), there continues to be a significant practice 
gap in relation to screening, referral, and treatment of depression in CVD patients (p. 
427). Although the American Heart Association recommends routine screening for 
depression in patients with cardiovascular disease, there are conflicting opinions among 
healthcare providers with regard to timing of screening and location of screening, 
especially in cardiology and primary care settings (Kronish, et al., 2012). Much of the 
research on depression in patients with CVD disease has occurred in the acute care 
setting (Lichtman, et al., 2008). With the emphasis in primary care management, 
improving outcomes, and decreasing hospital readmissions, primary care screening for 
depression in patients with CVD is essential and the ideal opportunity for long-term 
management (Kronish, et al., 2012).  
Currently, there is no standardized depression screening template for patients with 
cardiovascular disease in the primary care setting (Kronish, et al., 2012). There are many 
depression screening tools available for the primary care setting; however, the American 
Heart Association recommends the use of tools such as the Patient Health Questionnaire 
2-item screening tool (PHQ-2) and/or Patient Health Questionnaire nine-item screening 
tool (PHQ-9) due to the ease of use, reliability, and validity of the PHQ questionnaires 
(McGuire, et al., 2015, p. 429). The PHQ has also been easily implemented into 
electronic medical record (EMR) systems for general use. Ideally, implementation of 
these screening tools into the EMR would routinely alert the provider to perform the 
screening.  
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The PHQ-2 comprises the first two questions in the PHQ-9 questionnaire. As 
McGuire, et al., (2015) discusses, the PHQ-2 screening scale is the best brief screening 
instrument for use during a routine visit intake or annual physical examination survey. 
According to the American Psychological Association (2016), the PHQ-2 inquires about 
the degree to which an individual has experienced a depressed mood and anhedonia over 
the past two weeks. Its purpose is not to establish a final diagnosis or to monitor 
depression severity, but rather to screen for depression (APA, 2016). Patients who screen 
positive should be further evaluated with the PHQ-9 to determine whether they meet 
criteria for a depressive disorder (APA, 2016). If the PHQ-2 is negative, the provider may 
continue with the remainder of the assessment and does not need to complete the PHQ-9 
unless desired (McGuire, et al., 2015). 
The PHQ-9 is a nine-item self-report measure developed to diagnose the presence 
and severity of depression in primary care (Stafford, Hons, Berk, & Jackson, 2007). It is 
based directly on DSM-IV diagnostic criteria for major depression (Stafford, et al., 2007). 
It has the potential of being a dual-purpose instrument that, with the same nine items, can 
establish depressive disorder diagnoses using a categorical algorithm and grade the 
depressive symptom severity (Stafford, et al., 2007). As a severity measure, the score on 
the PHQ-9 can range from 0 to 27. Scores of 5, 10, 15 and 20 represent thresholds 
demarcating the lower limits of mild, moderate, moderately severe and severe depression, 
respectively (Stafford, et al., 2007). In multiple studies, PHQ-9 scores > 10 have been 
found to have a sensitivity of 88% and a specificity of 88% for Major Depressive 
Disorder (APA, 2016). 
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The PHQ questionnaires have been shown to be valid and reliable and have been widely 
utilized in studies with cardiac patients (Stafford, et al., 2007). The opportunity to screen 
for depression in cardiac patients should not be missed, as effective treatment of 
depression in these patients will lead to improved health outcomes (McGuire et al., 
2015). 
1.4 Discussion of Practice Innovation/Best Practices to Address Problem 
Early detection of depression in patients with cardiovascular disease has been 
shown to improve outcomes in these patients (Lichtman, et al., 2008). During primary 
care visits, the provider should administer the simple and quick PHQ-2 question survey in 
order to screen for depression, thereby, following AHA guidelines and recommendations. 
Studies have shown that these patients are not routinely screened for depression in other 
settings (Kronish, et al., 2012). 
1.5 Statement of the Purpose/Problem 
The purpose of this evidence-based project is to implement a standardized 
approach for depression screening for cardiovascular patients in the primary care setting 
in order to more accurately and efficiently assess the severity of depression in these 
patients and treat them in a timelier manner. Currently, there is not a routine screening 
process for depression in the primary care setting for cardiovascular patients.  
1.6 Project Questions 
 What is the best depression screening tool for implementing into a primary care 
setting for screening among patients with CVD for early detection? What evidence 
identifies timely and efficient screening of depression in patients with cardiovascular 
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disease?  What research is available on the importance of detection of depression in 
cardiac patients? What research is available on depression screening in the primary care 
setting?   
1.7 PICOT Question and Definitions 
 For providers in primary care settings who manage CVD patients, is the use of 
PHQ questionnaires utilized as a depression screening tool more efficient and effective as 
compared to no routine screening and sporadic screening with multiple tools? The 
population (P) in this study is providers in primary care who manage primary care 
patients with cardiovascular disease, and the intervention (I) is providers utilizing the best 
screening tool for depression in patients with CVD. The following will be measures to 
assess the intervention: screening for depression, medication therapy, and referral for 
counseling. The comparison (C) for this study is the current practice of providers’ 
utilization of multiple tools for screening for depression in CVD patients; however, there 
is no routine, standardized process in place in primary care settings. The outcome (O) 
will be to identify and implement the best screening tool for depression in patients with 
CVD. 
 1.8 Definitions 
1. Depression. The Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV, 2000) describes depression as a depressed mood and/or loss of interest or 
pleasure in life activities for a duration of at least two weeks and at least five of the 
following symptoms that cause clinically significant impairment in social, work, or other 
important areas of daily functioning
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Table 1.1 PICOT Definitions 
Population Current 
Practice 
Intervention Outcome Time 
60 patients 
age 18 years 
and older with 
documented 
cardiovascular 
disease (chart 
audits). 
Providers in 
Primary Care 
who manage 
Primary Care 
patients with 
CV disease 
Currently, 
providers use 
multiple tools 
for Screening 
for Depression 
in Primary 
Care patients 
with CV 
disease, but no 
standardized 
screening 
process 
Providers use 
the best 
Screening Tool 
for Depression 
in Patients with 
CV disease. 
 
Identify and 
Implement the 
best screening 
tool for 
depression in 
Primary Care 
patients with 
CVD as 
measured by: 
50% provider 
documentation 
of using the 
screening tool 
and 
subsequent 
management 
(counseling, 
medication) 
6-month review 
of 
implementation 
of depression 
screening for 30 
patients at 
routine Primary 
Care visits 
 
 
 10 
 
 
Depressed mood most of the day, diminished interest or pleasure in all or most 
activities; significant unintentional fluctuations in weight; insomnia or 
hypersomnia; agitation or psychomotor dysfunction; fatigue or loss of energy, 
feelings of worthlessness or guilt; diminished ability to think or concentrate; 
and suicidality (USDHHS, 2008).  
1. Cardiovascular Disease. The American Heart Association (2016) describes 
cardiovascular disease as a multitude of individual diseases of the heart and 
vasculature, including structural heart disorders and blood clots.  
2. Screening Tools. A screening tool is a simple test which is performed on a 
large number of people to identify those who have or are likely to develop a 
specific disease. Often these screening tests have a high sensitivity and 
moderate specificity (Medical Dictionary, 2016). 
3. Primary Care. Primary care is the level of a health system that provides entry 
into the system for all new needs and problems, and it provides a home for 
patients to manage new problems as well as chronic conditions.  
4. Health Care Provider.  A health care provider is defined as one who renders 
medical care or health services to patients, including physicians, nurse 
practitioners, physician assistants, and others (Medical Dictionary, 2016). 
5. Adult Patients. An adult patient will be defined as a patient who is 18 years 
of age or older with cardiovascular disease. 
1.9 Assumptions 
Patients diagnosed with cardiovascular disease deserve routine, standardized 
screening of depression in primary care settings since depression may severely affect 
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morbidity and mortality. Evaluation of evidenced-based practice can identify best 
practice measures to identify and treat depression in this population.  Implementation of 
depression screening tools can reduce suffering of patients and yield better outcomes for 
their overall health status. PHQ-2 and PHQ-9 questionnaires are effective and efficient 
screening tools for depression, and the American Heart Association has strongly 
recommended these tools as the gold standard for cardiovascular patients. Provider 
education is imperative to understanding the importance of detection and treatment of 
depression in these patients.  Identifying and appraising quality evidence from current 
research is important to change current clinical practice guidelines that lead to improved 
patient outcomes.  
1.10 Chapter Summary 
Depression and CVD are highly prevalent in the United States. Persons with CVD 
have more depression than the general population. Persons with depression are more 
likely to eventually develop CVD and also have a higher mortality rate than the general 
population. In order to minimize morbidity and mortality, it is crucial to understand that 
depression and CVD are frequently co-morbid and that both conditions should be treated 
concomitantly. To screen for depression in these patients, an appropriate, standardized 
screening approach should be utilized by providers and staff. The PHQ screening tools 
are a cost-effective, reliable, valid, and time-efficient approach to improving patients’ 
quality of life. 
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Chapter 2 Literature Review 
      Evidence-based research has been utilized to facilitate process improvement in 
our continuously evolving healthcare system.  It has been essential for healthcare 
clinicians to possess the skills of critically appraising evidence and distinguish best 
evidence from unreliable evidence (Melnyk & Fineout-Overholt, 2015).  A systematic 
literature review was performed with the purpose of identifying evidence that supports 
screening for depression in primary care patients with cardiovascular disease. The 
purpose of this study is to determine the best screening depression tool and implement the 
tool for early detection of depression in primary care settings for patients with 
cardiovascular disease. 
2.1 Search Methodology 
The identification of depression screening tools utilized in cardiac patients was 
generated based on a comprehensive search of databases accessed through the University 
of South Carolina’s online library. The literature has been extensively reviewed through 
use of CINAHL Complete and Cochrane Library electronic databases. The most frequent 
key words and phrases that were used in the searches included “depression,” 
“cardiovascular,” and “screening.” These specific search terms focus on the PICOT 
question and definitions. For the majority of the search iterations, the search terms 
“depression” and “cardiovascular” were used together or with an additional modifier. 
 13 
 
The initial search was undertaken in CINAHL Complete (2006-2016) through the 
Thomas Cooper Library. The limiters “Full Text” and “English” were utilized for all 
searches within this database. For the initial search, the terms “depression” and 
“cardiovascular” were used, and this search returned 1,004 results, which was further 
narrowed by the third search term “screening.” This search yielded a total of 53 results of 
which four articles were chosen due to relevance to PICOT question and due to the high 
quality of evidence. Another similar search in CINAHL included the search terms 
“depression,” “cardiovascular,” and the additional modifier “randomized trial.” This 
search resulted in 48 articles, and four of these articles were found to be applicable to the 
PICOT question. 
The next search was conducted in Cochrane Library with limiters of “Trials” and 
“2006-2016.” The search terms utilized for this search were “depression, coronary heart 
disease, and randomized.” This search yielded 51 results of which four articles were 
chosen for relevance to the PICOT question. Another search was undertaken in CINAHL 
Complete with the keywords “depression” and “coronary heart disease,” and this search 
returned 19 results of which three were found to be applicable to the PICOT question. 
Inclusion and exclusion criteria were established for the purpose of selecting 
appropriate studies to address the PICOT question. For inclusion criteria, the searches 
were limited to English language articles only. Also, higher levels of evidence were the 
only types of articles included in the selection process, specifically Levels I-IV (Melnyk 
& Fineout-Overholt, 2015). Evidence ratings (Level I-IV) and quality ratings for the 
literature are based on Dearholt & Dang’s (2012) book John Hopkins Nursing Evidence-
Based Practice: Model and Guidelines. 
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Exclusion criteria included non-English language studies, as well as studies published 
before 2006. There were many descriptive and qualitative studies in several of the 
searches, but these were excluded from the evidence table at this time due to evidence 
ratings. However, several of the descriptive and qualitative studies were set aside due to 
quality ratings. 
After evaluation of the articles using inclusion and exclusion criteria, the choices 
were narrowed to fifteen articles which were most appropriate for the topic and were 
good to high quality evidence. In the evidence table (see Appendix A), there are fifteen 
articles, which are Level I through Level IV evidence according to John Hopkins’ model 
(Dearholt & Dang, 2012). There are a variety of types of studies contained within the 
table, including systematic reviews, meta-analyses, randomized controlled trials, a quasi-
experimental study, cohort studies, and clinical practice guidelines from the American 
Heart Association. Of the fifteen included articles, there are 5 randomized controlled 
trials, and several of these are double-blind studies. According to Melnyk and Fineout-
Overholt (2015), “randomized control trials are the most appropriate research design to 
answer questions of efficacy and effectiveness of interventions because their 
methodology provides confidence in establishing cause and effect” (p. 116).  
According to Melnyk and Fineout-Overholt (2015), critical appraisal hinges on 
validity, reliability, and applicability (p.87). The database search generated the fifteen 
selected articles that were placed in a literature review table (see Appendix A) then 
utilized for their analysis and synthesis.  In this table, there is discussion of the limitations 
of each study, including threats to internal validity, external validity, and reliability. 
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2.2 Analysis of Evidence 
Current research has been analyzed to identify common symptoms, 
pathophysiology, treatment, and implementation of screening tools for depression in 
patients with cardiovascular disease. Analysis of literature has been a significant process 
utilized to support changes in current practice, policies, and guidelines.  
Depression Symptoms and Comorbidities. Dysphoria, insomnia or 
hypersomnia, anhedonia, fatigue or loss of energy, increased guilt or worthlessness, 
decreased concentration, appetite changes, psychomotor dysfunction, and suicidal 
ideation are the symptoms of depression and exist on a vast continuum of severity and 
complexity (McGuire et al., 2015, pp. 422-423).  In one double-blind randomized control 
trial, higher depression scores were associated with an increased risk of a subsequent 
cardiovascular event, mortality, and possibly dementia (Peters, Pinto, Beckett, Swift, 
Potter, McCormack,… Bulpitt, 2010).  This was a double-blind RCT of 2,656 
participants. The HYVET was a randomized double-blind, placebo-controlled trial and 
employed an antihypertensive treatment regimen of indapamide sustained release 1.5 mg 
with the optional addition of perindopril 2–4 mg. Ethical and regulatory approvals were 
obtained prior to data collection. Depression scores were collected using the 15-item 
GDS (geriatric depression scale) administered as part of a Quality of Life (QoL) 
questionnaire at baseline and annually thereafter (Peters, et al., 2010). The researchers 
found that a GDS score of ≥6 was associated with an increased risk of all-cause and 
cardiovascular mortality and cardiovascular morbidity. Mood was found to be worse in 
those who previously had a cardiac event.  GDS score ≥6 was associated with increased 
risks of all-cause (HR 1.8, 95% CI: 1.4–2.3; p <0.001) and cardiovascular mortality (HR 
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2.10, 95% CI: 1.5–3.0; p <0.001), all stroke (HR 1.8, 95% CI: 1.2–2.8; p 0.002) and all 
cardiovascular events (HR 1.6, 95% CI: 1.2–2.1; p 0.001). Risk of incident dementia also 
tended to be increased (HR 1.28, 95% CI: 0.95–1.73; p 0.110). This study also found that 
there is an increased risk of all-cause and cardiovascular mortality and cardiovascular 
morbidity in patients who suffer from the above listed depressive symptoms (Peters, et 
al., 2010).   
The study concluded that a depressed mood is common in older people with 
hypertension (Peters, et al., 2010). Higher depression scores were associated with an 
increased risk of a subsequent cardiovascular event, mortality and possibly dementia 
(Peters, et al., 2010). The researchers suggest that further studies would require 
replication and exclusion of some alternative possibilities before testing in an 
intervention trial (Peters, et al., 2010).  
This double-blind RCT helps to significantly minimize threats to internal validity 
by reducing selection bias (Dearholt & Dang, 2012). The size of the study was large 
which minimizes threats to validity. The subjects in each of the groups were similar with 
regard to demographic and baseline clinical variables, which makes the results more 
generalizable. Baseline demographics were clearly displayed in a table to complement the 
discussion in the article. Although participants were unable to enter the study if they 
required nursing care, the researchers did not collect rigorous information about activities 
of daily living, disability levels or maintenance of social networks, socioeconomic status 
or activity level. Therefore, there is the potential for uncontrolled confounding from 
unmeasured factors. According to Dearholt and Dang (2012), the study is Level I 
Evidence with a high quality rating (A).  
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Mavrides and Nemeroff (2013) found that the prevalence of major depressive 
disorder (MDD) in patients with CAD, including stable and unstable angina or MI, is 
estimated to be between 15 and 20%. They also found that another estimated 30–45% 
have clinically significant depressive symptoms without meeting DSM-IV or DSM-V 
(Diagnostic and Statistical Manual of Mental Disorders fourth and fifth editions) criteria 
for MDD (Mavrides & Nemeroff, 2013, p. 329). This study was a systematic review of 
61 randomized controlled clinical trials. PubMed and PsycINFO databases were searched 
through July 2012. No trials were excluded, and the studies included were primarily from 
North America and Europe. The search was completed with key words of 
antidepressants, CVD, coronary artery syndrome, SSRIs, depression, treatment of 
depression, post-MI, major depression, and cardiac disease (Mavrides & Nemeroff, 
2013). These researchers found that depressive symptoms are especially prevalent in 
patients recently hospitalized with acute cardiac events, with a depression prevalence rate 
of 20-36% in patients recently hospitalized with congestive heart failure (Mavrides & 
Nemeroff, 2013). In addition, depressive symptoms often persist indefinitely in patients 
with CVD, partly due to under diagnosis and partly due to a lack of treatment or 
inadequate treatment. In the progression of post-MI depression, symptoms generally 
remain fairly consistent in terms of severity for up to 12 months (Mavrides & Nemeroff, 
2013). Several mechanisms, behavioral and physiologic, have been implicated in the 
connection between depression and cardiac disease, including alterations in platelet 
function, inflammation, variability in heart rate, and adrenocortical hyperactivity 
(Mavrides & Nemeroff, 2013, p. 330). The studies contained in this review are 
randomized control clinical trials, and this helps to minimize threats to internal validity. 
 18 
 
 
The authors stated that they limited search results to the English language. By limiting to 
English only, the researchers risk biasing the amount of research they may find with 
regard to their research topic. The number of studies reviewed is 61, which helps to limit 
threats to external validity. The results were consistent across all studies increasing the 
generalizability of the results to the general population. The authors displayed their 
results of all utilized clinical trials in an evidence table, and discussed odds ratios (OR), 
effect sizes, and confidence intervals (CI) for the trials. The researchers compared the 
results of each study, which limits threats to reliability in this review. Based on criteria by 
Dearholt and Dang (2012), this study is Level I Evidence and has a high-quality rating 
(A). 
In one prospective cohort study with 960 participants, the researchers found that 
higher baseline depressive symptoms over five years predicted greater risk of functional 
decline in patients with CVD (Sin, Yaffe, & Whooley, 2014). Cardiovascular severity 
assessments were obtained at baseline and again at 5 years. The severity of depressive 
symptoms was assessed at baseline and at the 5-year follow-up using the 9-itme Patient 
Health Questionnaire (PHQ). In models that tested each cardiovascular predictor 
separately, baseline depressive symptoms and angina pectoris frequency were associated 
with greater risk of functional decline during the 5-year period, whereas higher baseline 
exercise capacity predicted lower risk of ADL and IADL decline (p < .001) (Sin, Yaffe, 
& Whooley, 2014). These results suggest that efforts to treat and decrease depressive 
symptoms may be as important as treating actual symptoms of cardiovascular disease to 
enhance functional status (Sin, Yaffe, & Whooley, 2014). This study had a large sample 
size, which strengthens the validity; however, the sample was largely male which limits 
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the generalizability of the results (Sin et al., 2014). This study is Level III Evidence with 
a quality rating of A (Dearholt & Dang, 2012). 
In one systematic review, the literature revealed that CVD and Depression are 
both highly prevalent diseases, which have been shown to frequently coexist (Paz-Filho, 
Licinio, & Wong, 2010). This study is a literature review of a combination of RCTs, 
quasi-experimental studies, and non-experimental studies in which the reviewers utilized 
the PubMed database in order to describe the pathophysiological link between 
cardiovascular disease and depression (Paz-Filho, 2010). In this study, researchers found 
that depression and CVD share common pathophysiological etiologies or co-morbidities, 
such as alterations in the hypothalamic-pituitary axis and serotoninergic changes (Paz-
Filho, 2010). There is compelling evidence that depression is an independent risk factor 
for both the development of CVD and for worsening prognosis (Paz-Filho, 2010).  
Evidence has also shown that patients with CVD may become depressed as a 
response to the burden of a co-morbid condition (Paz-Filho, 2010). Several non-
experimental studies were included in this review which increases the threat to internal 
validity (Paz-Filho, 2010).  The results were consistent across all studies increasing the 
generalizability of the results to the general population (Paz-Filho, 2010). This study is 
Level III Evidence with a good quality rating (B) (Dearholt & Dang, 2012).  
In addition to the co-morbidity correlation between CVD and Depression, one 
clinical review showed that there is strong evidence to suggest that depression is 
associated with an increased risk of cardiovascular disease and cardiac death (Hare, 
Toukhsati, Johansson, & Jaarsma, 2014). This is a clinical review of five major 
randomized controlled trials with the purpose of evaluating the effects of anti-depressant 
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pharmacotherapy on depression in cardiovascular disease settings (Hare, et al., 2014). 
Researchers found that patients with depression and comorbid CVD have a higher 
mortality rate than the general population (Hare, et al., 2014). Evidence has shown a 
severity relationship between depression and CVD: the more severe the depression, the 
higher the subsequent risk of mortality and other cardiovascular events (Hare, et al., 
2014). In this review, a total of five randomized control trials were reviewed, and the 
researchers felt that these were all high quality evidence. The five trials included 
significant numbers of patients ranging from 101 to 2,481 (Hare, et al., 2014). However, 
the low number of studies included limits the validity of the review (Hare, et al., 2014). 
This study is Level III Evidence with a good quality rating (B) (Dearholt & Dang, 2012).  
Depression Screening. It is highly recommended to promptly assess depression 
in patients with cardiovascular disease as it represents a crucial risk factor which may 
result in worsening cardiac symptoms and premature death following cardiac events 
(Mavrides & Nemeroff, 2013). Many screening tools are available for evaluation of 
patients with depressive symptoms (Mavrides & Nemeroff, 2013). 
The Hospital Anxiety and Depression Scale (HADS) is one of the simplest and 
most widely utilized screening instruments for depression (Ceccarini, Manzoni, & 
Castelnuovo, 2014). This screening tool utilizes a simple 14-item Likert-scale type of 
scoring, and has been found to reliably detect depressive symptoms in post-MI patients in 
the inpatient setting.  The questionnaire was designed to provide a reliable tool within the 
clinical practice and it is composed of 7 questions which identify the level of anxiety and 
7 questions which relate to depression. The authors created this outcome measure 
specifically to avoid excessive reliance on other aspects which are intertwined with 
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anxiety and depression (Ceccarini, et al., 2014). Items of the Hospital Anxiety and 
Depression Scale (HADS) are scored from 0 to 3 on a Likert scale with a final score 
ranging from 0 to 21 for either anxiety or depression (Ceccarini, et al., 2014). The total 
score is used as a measure of global mood disorder according to the classifications of 
mild (8-10), moderate (11-15), and severe anxiety or depression (16-21). Zigmond and 
Snaith (1983) performed the validation study for this screening tool. They found that 
internal and test-retest reliabilities of both total and subscale scores were generally good 
as the questionnaire allowed to determine subscale factors assessing dimensions of 
anhedonia, anxiety, and psychomotor agitation (Ceccarini, et al., 2014). The Hospital 
Anxiety and Depression Scale (HADS) is hence a reliable instrument useful to screen and 
evaluate post-MI patients for symptoms of psychological distress. This tool has several 
disadvantages or limitations, including its weakness in detecting actual severity of 
depression (Ceccarini, et al., 2014). 
Another tool, the Cognitive Behavioral Assessment Hospital Form (CBA-H), is 
also a common type of inpatient screening instrument, which has been used 
internationally to discriminate between emotional states and behavioral changes related to 
the current hospitalization or health diagnosis (Ceccarini, et al., 2014). Bertolotti, 
Sanavio, and Zotti (2002) conducted a validation study for this screening tool in Italian 
hospital, and this has since been considered a valid and reliable tool for general 
psychological distress screening within the hospital context (Ceccarini, et al., 2014). The 
CBA-H is composed by four cards: A, B, C, and D. Card A contains 21 items focusing on 
the present time and investigates the emotional state at the time of test completion (i.e., 
hospitalization). Card B contains 23 items asking about the previous three months 
 22 
 
 
investigating on dysphoria and on other psychophysiological disorders and stress 
(Ceccarini, et al., 2014). Card C contains 61 items focusing on the period of time prior to 
the disease and it asks a self-reported patient description of his/her stable character and 
behavior such as introversion/extroversion, neuroticism, social anxiety, speed and 
impatience, job involvement, hostility, hard driving, and irritability (Ceccarini, et al., 
2014). Card D contains 47 items on biographical information about general lifestyle 
(work, affective and sexual life, smoking, eating and drinking, sleep quality, and physical 
exercise) and health risk factors (Ceccarini, et al., 2014). A limitation to this tool is its 
excessive number of questions (Ceccarini, et al., 2014). The questionnaire contains 147 
items with a true and false answering system. Also, this tool does not specifically target 
the population of cardiac patients, although these patients may be included for screening 
(Ceccarini et al., 2014). 
 A third commonly utilized and studied screening instrument is the Beck 
Depression Inventory (BDI-II), which consists of 21 items (Ceccarini et al., 2014). Beck, 
Steer, and Brown (1996) developed the screening tool and conducted a validation study, 
which showed a strong test-retest reliability for this tool (Ceccarini et al., 2014). The 
Beck depression tool assesses the severity of 21 depression symptoms rated on a 4-point 
scale (0-3). The tool consists of 13 items which address cognitive or affective symptoms, 
and the remaining 8 items assess somatic symptoms such as insomnia and fatigue. BDI 
total scores of 10-18 are consistent with mild depression, 19-29 with moderate 
depression, and 30 or higher with severe depression (Ceccarini, et al., 2014). The tool has 
been supported by a consistent number of studies, and it is known to correspond with 
over 90% of clinical diagnoses for patients who suffer from depression (Ceccarini, et al., 
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2014). However, it must be noted that this tool can only be used to measure the severity 
of depression and is not necessarily utilized as a diagnostic tool (Ceccarini, et al., 2014). 
This limits its use to a measurement of depressive symptoms, and it leaves the provider to 
make the initial diagnosis through other means. 
Lastly, there is a screening instrument for depression in cardiac patients which is 
considered the gold-standard of screening tools in this population of patients (Ceccarini, 
et al., 2014). This tool is known as the Patient Health Questionnaire (PHQ-2 and PHQ-9). 
The American Heart Association (AHA) recommends using the Patient Health 
Questionnaire (PHQ-2) at minimum (Lichtman, et al., 2008). This tool provides two 
questions that are recommended for identifying currently depressed patients, and if 
positive on either or both questions, it is recommended that all nine PHQ items (PHQ-9) 
be asked (Lichtman, et al., 2008). The PHQ-9 is based directly on DSM-IV diagnostic 
criteria for major depression, and this tool has shown to be valid and reliable after having 
been widely utilized in studies with cardiac patients (Stafford, Hons, Berk, & Jackson, 
2007). One study by Stafford, et al., (2007) investigated the validity of the PHQ 
instruments relative to a referent diagnostic standard in recently hospitalized patients with 
CAD. Three months post-discharge for a cardiac admission, 193 CAD patients completed 
the PHQ-9 (Stafford, et al., 2007). The Mini International Neuropsychiatric Interview 
(MINI) was the criterion standard (Stafford, et al., 2007). In this study, scale reliability 
was calculated using Cronbach's α. Convergent validity was computed using Pearson's 
intercorrelations (Stafford, et al., 2007). The internal consistencies for the self-report 
questionnaire were excellent with Cronbach's α coefficient of 0.90 for the PHQ-9 
(Stafford, et al., 2007). The questionnaire was found to have a sensitivity of 81.5% and a 
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specificity of 80.6% (Stafford, et al., 2007). This brief, sensitive, and specific screening 
tool may be completed in less than five minutes by a provider or self-administered by the 
patient in the same short time period (Lichtman, et al., 2008). This tool has been shown to 
be efficient in the detection of depression, and it may also be used in follow up 
assessments after the initial diagnosis has been made which adds to its usefulness in 
practice (Lichtman, et al., 2008). 
Depression Treatment. Despite the high prevalence rate of major depression and 
minor depressive symptoms in cardiac patients and their poor prognosis for survival and 
quality of life, comparatively few receive treatment for their depressive disorder 
(Mavrides & Nemeroff, 2013, p. 332). There are many reasons for this occurrence, 
including under-diagnosis and provider reluctance to initiate treatment due to concerns 
about the safety of antidepressant medications, including the potential for medication 
interactions or unwanted cardiac adverse effects. According to Sin et al., (2014), 
researchers have found that efforts to treat and decrease depressive symptoms may be as 
important as treating actual symptoms of cardiovascular disease to enhance functional 
status. The treatment of depression in patients with cardiovascular disease has shown to 
increase overall survival, and this should be considered by providers caring for patients 
with CVD.  
The most commonly utilized Pharmacotherapy treatment choices for depression 
in patients with cardiovascular disease include sertraline, escitalopram oxalate, 
venlafaxine hydrochloride, bupropion hydrochloride (Davidson, Rieckmann, Clemow, 
Schwartz, Shimbo, Medina, … Burg, 2010).  Short-term treatment of depression with 
tricyclic antidepressants (TCAs) is relatively safe in patients with cardiovascular disease; 
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however, long-term treatment has not been well studied, and orthostatic hypotension is a 
serious complication observed with some TCAs (Davidson, et al., 2010). Therefore, 
TCAs should be used cautiously in patients with cardiovascular disease, especially those 
with baseline postural systolic blood pressure reductions (Davidson, et al., 2010). 
Bupropion has been found to be safe in patients with cardiovascular disease although 
more studies are needed for this treatment (Davidson, et al., 2010).  
One systematic review of randomized control trials found that there is 
considerable evidence that antidepressants, especially SSRIs, are safe in the treatment of 
major depression in patients with CVD (Mavrides & Nemeroff, 2013). This was a 
systematic review of 61 randomized controlled clinical trials retrieved from the databases 
PubMed and PsycINFO (Mavrides & Nemeroff, 2013). No trials were excluded, and the 
studies included were primarily from North America and Europe (Mavrides & Nemeroff, 
2013). The studies contained in this review are randomized control clinical trials, and this 
helps to minimize threats to internal validity (Mavrides & Nemeroff, 2013). In this 
review, 7 clinical trials of tricyclic antidepressants (TCAs), one of TCAs and bupropion 
together, were included, and 10 clinical trials of selective serotonin reuptake inhibitors 
(SSRIs) were included as well (Mavrides & Nemeroff, 2013). This review’s results were 
consistent across all studies, thereby increasing the generalizability of the results to the 
general population of patients with cardiovascular disease.  
Raskind et al. (1982) studied 12 men with ischemic heart disease, post-MI and 
CABG, who met criteria for secondary major depression, defined as depression that 
follows a major illness (Mavrides & Nemeroff, 2013). The goals were to evaluate 
changes in cardiac conduction, frequency of orthostatic hypotension, and the efficacy of 
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the antidepressant imipramine (Mavrides & Nemeroff, 2013). The authors of this study 
concluded that imipramine was safe in a patient with stable ischemic heart disease and 
minimal conduction defects; however, if a person had pretreatment orthostatic 
hypotension, the frequency of orthostatic hypotension with imipramine should be 
considered and prescribed cautiously (Mavrides & Nemeroff, 2013). Imipramine and 
doxepin were evaluated by Veith et al. in a randomized, double-blind, placebo-controlled 
trial of 24 patients, of whom 23 had experienced an MI, 8 had coronary artery bypass 
graft (CABG) surgery, one had a pacemaker, and one had a prosthetic heart valve 
(Mavrides & Nemeroff, 2013). The purpose of the study was to evaluate the effects of 
imipramine and doxepin on cardiac conduction and determine the antidepressant efficacy 
in depressed patients with cardiac disease (Mavrides & Nemeroff, 2013). Veith et al. 
concluded that post-MI patients could safely be treated with either imipramine or 
doxepin, though if they are at risk for developing orthostatic hypotension, they should 
receive alternative treatments (Mavrides & Nemeroff, 2013).  
Glassman et al. (1983; 2011) evaluated the use of imipramine in depressed 
patients with left ventricular impairment in a prospective trial with 15 depressed patients 
undergoing radionuclide angiography (Mavrides & Nemeroff, 2013). Patients received 
imipramine and the dose gradually increased to 3.5 mg/kg/day over the course of 3 
weeks; the radionuclide angiography was then repeated (Mavrides & Nemeroff, 2013). 
Only 11 of the 15 patients completed the entire 3-week treatment period because of 
adverse effects (Mavrides & Nemeroff, 2013). Of those who completed the treatment 
period, imipramine was reported to be effective in treating the depressive symptoms, 
though no information was provided regarding how this was assessed and measured 
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(Mavrides & Nemeroff, 2013). Glassman et al. concluded that although imipramine does 
not affect ventricular function, orthostatic hypotension was clinically significant and 
clearly needs to be monitored (Mavrides & Nemeroff, 2013).  
In a similarly designed study, Roose et al. (1986) evaluated the effects of 
nortriptyline in 21 depressed patients with decreased left ventricular ejection fraction 
(Mavrides & Nemeroff, 2013). The authors suggested that nortriptyline might be a safe 
medication for the treatment of depression in patients with heart failure (Mavrides & 
Nemeroff, 2013). Roose et al. conducted another trial comparing imipramine (3.5 
mg/kg/day) and nortriptyline (1.4 mg/kg/day) in 196 depressed patients with cardiac 
conduction disease (Mavrides & Nemeroff, 2013). The patients were enrolled for over 10 
years (Mavrides & Nemeroff, 2013). Both nortriptyline and imipramine were found to be 
effective antidepressants, with nortriptyline causing less cardiac side effects (Mavrides & 
Nemeroff, 2013). The authors concluded that in patients with cardiac conduction deficits, 
with or without heart failure, nortriptyline is preferable to imipramine (Mavrides & 
Nemeroff, 2013). Dietch et al. (1987) studied 10 elderly, depressed patients with cardiac 
conduction disease treated with nortriptyline with the primary goal to evaluate EKG 
changes associated with the medication (Mavrides & Nemeroff, 2013). Each patient had 
abnormal EKGs at baseline, with first-degree AV block, hemi-blocks, bundle branch 
blocks, and bradycardia (Mavrides & Nemeroff, 2013). Nortriptyline was effective in 
treating depressive symptoms of elderly patients and was associated with minimal risk in 
patients with conduction disease (Mavrides & Nemeroff, 2013).  
Cohen et al. (1993; 2010) evaluated trimipramine in an open study of 22 patients 
with mild heart disease and mild to moderate depression in a 28-day trial (Mavrides & 
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Nemeroff, 2013). Depression severity was assessed using the CGI Scale and Hamilton 
Depression Scale (HAM-D). The goal of the trial was to evaluate the efficacy of 
trimipramine and monitor cardiac changes and adverse effects (Mavrides & Nemeroff, 
2013). Trimipramine seemed to be safe and effective for depression in patients with mild 
heart disease (Mavrides & Nemeroff, 2013). Roose et al. compared the effects of 
imipramine and bupropion in depressed patients with heart failure in a double-blind 
crossover study, which was comprised of 10 patients (Mavrides & Nemeroff, 2013). 
Bupropion and imipramine were equally efficacious in the treatment of depression 
(Mavrides & Nemeroff, 2013). The authors concluded that bupropion was safer than 
imipramine for use in depression accompanied by heart failure secondary to the low 
frequency of orthostatic hypotension and negligible effects on left ventricular function 
(Mavrides & Nemeroff, 2013).  
A small double-blind, randomized, controlled 6-week trial comparing paroxetine 
to nortriptyline in 81 patients with both depression and ischemic heart disease assessed 
the efficacy and cardiovascular safety of the two medications (Mavrides & Nemeroff, 
2013). Although paroxetine and nortriptyline were both effective antidepressants, 
nortriptyline was associated with significantly more frequent and serious cardiac events 
than paroxetine (Mavrides & Nemeroff, 2013). Roose and colleagues used a historical 
control group to compare the potential cardiovascular effects of fluoxetine and 
nortriptyline, 27 patients received the SSRI and 60 patients received the TCA (Mavrides 
& Nemeroff, 2013). Although this was a historical controlled non-prospective trial, 
fluoxetine did not exhibit the cardiovascular side effects that were observed with 
nortriptyline (Mavrides & Nemeroff, 2013).  
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Additional evidence from a clinical trial that SSRIs might be beneficial and safe 
in cardiac patients came in 1999, when Shapiro et al. performed an open-label study 
evaluating the safety, tolerability, and efficacy of sertraline in post-MI patients in the 
Sertraline Antidepressant Heart Attack Trial (SADHAT). Sertraline led to improvement 
in depressive symptoms without any increased risk of adverse cardiac events. Further 
evidence of the potential efficacy of SSRIs in CVD patients came from a double-blind, 
placebo-controlled trial of fluoxetine (Mavrides & Nemeroff, 2013). In this 25-week 
study, 54 patients with depression and recent MI were enrolled (Mavrides & Nemeroff, 
2013). The authors concluded that fluoxetine is a safe and effective antidepressant in 
patients who are post-MI (Mavrides & Nemeroff, 2013). Further evidence for the efficacy 
of SSRIs in depressed patients with cardiac disease is derived from the Canadian Cardiac 
Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) study. 
This 2 × 2 factorial designed trial evaluated the efficacy of IPT and citalopram in 284 
patients with CAD over a 12-week period (Mavrides & Nemeroff, 2013). Surprisingly, 
some of the subgroup analyses suggested that clinical management may be more effective 
than IPT in patients with low baseline social support or poor day-to-day functioning 
(Mavrides & Nemeroff, 2013).  
Two large multicenter trials, ENRICHD and MINDIT assessed the treatment of 
depression in patients with MDD and CAD. In the ENRICHD trial (Enhancing Recovery 
in Coronary Heart Disease), 2,481 patients with acute MI and major depressive disorder, 
minor depressive disorder, or dysthymia were randomized to CBT or treatment as usual 
(Mavrides & Nemeroff, 2013). The group receiving CBT showed a small but statistically 
significant decrease in their depressive symptoms, but exhibited no change in the 
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incidence of cardiac events during the initial 6-month treatment period. In MIND-IT 
(Myocardial Infarction Depression Intervention Trial), 91 post-MI depressed patients 
were randomized to receive either mirtazapine or citalopram. Patients were followed for 
an average of 27 months (Mavrides & Nemeroff, 2013). The antidepressant efficacy of 
mirtazapine and citalopram was not superior to placebo (Mavrides & Nemeroff, 2013). 
Interestingly, patients who did not respond to antidepressant treatment exhibited a higher 
rate of cardiac events when compared to those who responded to the antidepressant 
(Mavrides & Nemeroff, 2013).  
In the SADHART-CHF trial, O’Connor et al. studied the antidepressant efficacy 
and cardiovascular safety of sertraline versus placebo in depressed patients with CHF. 
This was a 12-week randomized, double-blind, placebo-controlled trial (Mavrides & 
Nemeroff, 2013). Depression symptom severity was rated using the HAM-D, and patients 
were treated with sertraline (50–200 mg/day) or placebo in addition to nurse-facilitated 
support (Mavrides & Nemeroff, 2013). Of the 469 patients enrolled, 234 patients 
received sertraline and 235 patients received placebo. Sertraline was not superior to 
placebo (P = 0.89, 95% CI −1.7 to 0.9), though both groups exhibited a statistically 
significant reduction in HAM-D scores (P < 0.001). A significantly larger number of 
subjects in the sertraline group withdrew from the study due to medication side effects 
(27/234; 11.5%) compared to the placebo group (14/235; 6%; P = 0.03). There was no 
statistically significant difference in all-cause mortality between the groups (Mavrides & 
Nemeroff, 2013). The authors concluded that sertraline neither improved depression nor 
cardiac outcomes compared to placebo (Mavrides & Nemeroff, 2013). One of the 
possible limitations of the study was the relatively moderate severity of depression of the 
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patients that comprised the study (HAM-D scores were 19.9 in the sertraline group and 
18.4 in placebo).  
As concluded by Mavrides and Nemeroff (2013) in their systematic review, 
selective serotonin reuptake inhibitors (SSRIs) are considered to be the safest of the 
antidepressants for these patients with cardiovascular disease, and this class of 
antidepressants is associated neither with orthostatic hypotension nor conduction 
abnormalities (Mavrides & Nemeroff, 2013, p. 339). Furthermore, multiple randomized 
clinical trials have demonstrated that two SSRI antidepressants, sertraline and citalopram, 
are the safest for patients with cardiovascular disease and are effective for moderate, 
severe, or recurrent depression in this population of patients (Mavrides & Nemeroff, 
2013; Lichtman et al., 2008). This study is Level I Evidence with an excellent quality 
rating (A) (Dearholt & Dang, 2012). 
Depression Education for Patients, Families, and Interdisciplinary Team. 
One pilot study with a randomized controlled design evaluated psychosocial support and 
the effect of interdisciplinary team education for post-cardiac surgery heart failure 
patients (Agren, Berg, Svedjeholm, & Stromberg, 2014). The study included a total of 42 
patient-partner completed baseline assessments for evaluating psychosocial support and 
education from an interdisciplinary team approach. Patients with postoperative health 
failure and their partners were chosen to participate in 3 month and 12 month follow up 
phone interviews (Agren et. al., 2014). Randomization was performed using a random-
number table with block of 12 (Agren et. al., 2014). Several questionnaires were used, 
including a demographic questionnaire, Charlson Comorbidity Index, SF-36, Beck 
Depression Inventory, and Perceived Control (Agren et. al., 2014). Partners in the 
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intervention group increased health in the role emotional and mental health dimensions, 
and patients increased health in vitality, social function, and mental health dimensions as 
compared with the control group (Agren et. al., 2014). Patients’ perceived control 
improved significantly in the intervention group over time (Agren et. al., 2014). The 
results of this study suggest that psychoeducational support from a multidisciplinary team 
to post-cardiac surgery heart failure dyads (patient and partner) improves health and 
perceived control in patients after 3 and 12 months (Agren et. al., 2014). These results 
also suggest that interventions focusing on psychoeducational support can improve the 
life situation for the patient-partner and especially for the patients (Agren et. al., 2014). 
Psychoeducational support appears to be a promising intervention, but the results need to 
be confirmed in larger studies (Agren et. al., 2014). One limitation to this study is the 
relatively small sample of couples in the study, which poses a threat to external validity. 
There were also some inter-group differences and outcomes, which would limit 
generalizability. This study is Level I Evidence with a good quality rating (B) (Dearholt 
& Dang, 2012). 
2.3 Synthesis of Literature 
According to Melnyk and Fineout-Overholt (2015) synthesis is not a 
summarization of the articles identified as significant, but it is rather a process of critical 
thinking built on several principles of the synthesis. After a comprehensive analysis of 
the literature was performed, inferences were made to synthesize best practices for 
screening for depression in patients with cardiovascular disease.  Major depressive 
disorder and depressive symptoms are prevalent in the population of patients with 
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cardiovascular disease, especially those who have recently been hospitalized for a cardiac 
event (Peters, et al., 2010).  
Timely screening, detection, and treatment of depression in patients with 
cardiovascular disease may help to improve quality of life and increase overall survival 
for these patients (Sin, et al., 2014). Although screening tools have been condensed and 
are readily available to providers in primary care practices for their patients, synthesis of 
the literature has shown that screening for depression in CVD patients is not routinely 
undertaken in any setting, inpatient or outpatient (Lichtman, et al., 2008; Peters, et al., 
2010; Ceccarini, et al., 2014). Through comparison of the available depression screening 
tools, synthesis of the literature revealed that the PHQ-2 and PHQ-9 tools are the most 
brief, sensitive, and specific depression screening tool for patients with cardiovascular 
disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). Since the PHQ 
questionnaire can be easily self-administered by patients or by the healthcare provider in 
5 minutes or less, this tool is also considered the most time efficient of the depression 
screening tools (Ceccarini, et al., 2014). The PHQ questionnaire is also recommended by 
AHA as the most appropriate screening for this population of patients (Lichtman, et al., 
2008). Providers should be prepared to treat and refer these patients based on results of 
the individual screenings. Multiple safe treatment options exist for patients who test 
positive for depressive symptoms, and the provider should weight benefits and risks 
when deciding upon appropriate treatment regimens in patients with depression who have 
cardiovascular disease (Davidson, et al., 2010; Mavrides & Nemeroff, 2013). Overall, 
there is good evidence to implement the use of PHQ depression screening for 
cardiovascular patients in primary care. 
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2.4 Recommendations 
Based on the evidence illustrated from the selected studies in this review, 
recommendations have been identified to assist primary care providers in improving the 
quality and timeliness of care delivered to cardiovascular patients who are suffering from 
depression.  These recommendations have been graded according to Dearholt & Dang’s 
(2012) book John Hopkins Nursing Evidence-Based Practice: Model and Guidelines. 
The recommendations have been based on the quality and amount of evidence available 
to support the implications for guidelines, practice parameter, or clinical policy. 
1. Screening for Depression in Patients with CVD – Grade A (High Quality) 
Evidence. Psychological distress has a significant negative impact on patients 
with CVD and is often under-recognized by health care providers (Lichtman et 
al., 2008). Primary care providers and cardiovascular specialty providers are 
called upon to improve their recognition of psychological distress in their patients 
and assure referrals are made to collaborative care teams for proper diagnosis and 
treatment (Lichtman et al., 2008). At a minimum, the Patient Health 
Questionnaire (PHQ-2) provides two questions that are recommended for 
identifying currently depressed patients. If the answer is “yes” to either or both 
questions, it is recommended that all nine of the PHQ items (PHQ-9) be asked 
(Lichtman et al., 2008). For patients with mild symptoms, follow-up during a 
subsequent visit is advised at which time the PHQ-9 questionnaire may again be 
utilized for screening. In patients with positive depression scores, a provider or 
nurse should review the answers with the patient, and treatment options should be 
discussed with the patient (Lichtman et al., 2008).  
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2. Treatment of Depression in Patients with CVD – Grade A (High Quality) 
Evidence. There is considerable evidence from randomized controlled clinical 
trials that antidepressants, especially SSRIs, are safe in the treatment of major 
depression in patients with CVD (Mavrides & Nemeroff, 2013). Researchers have 
concluded that frequent and timely treatment adjustment by primary care 
physicians, along with increased patient self-monitoring, improved control of 
diabetes, depression, and heart disease (Mavrides & Nemeroff, 2013). Evidence 
also suggests that depressed patients who are not responsive to treatment for 
depression may be at greater risk for adverse cardiac events, but aggressive 
cardiologic care may help mitigate this increased risk. Depressed patients may 
also require additional clinical management to ensure compliance with cardiac 
treatment regimens and to promote lifestyle behavior change (Lichtman et al., 
2008). 
3. Provide education to the providers, staff, patients, and family members – 
Grade B (Good Quality) Evidence. 
Formal and clear procedures, mechanisms, regular case reviews, and peer staff 
development need to be in place in order to sustain a successful screening 
program and offer an environment which aids in bringing about the best outcome 
for the patient dealing with depression. Psychoeducational intervention has been 
found to reduce anxiety and depression in patients with cardiovascular disease, 
and educational interventions increase family satisfaction (Agren et. al., 2014). 
When the families and the patients are well-informed, there is a basis for fruitful 
and effective communication between them and the healthcare professionals 
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leading to increased compliance to treatment regimens and overall better 
outcomes (Agren et al., 2014). 
2.5 Chapter Summary 
Despite the devastating consequences, comorbid cardiovascular disease and 
depression remain poorly recognized and treated (Paz-Filho, 2010; Lichtman et al., 
2008). Primary care providers and cardiovascular specialty providers are called upon to 
improve their recognition of depression in their patients and assure referrals are made to 
collaborative care teams for proper diagnosis and treatment (Lichtman et al., 2008). 
There is a vast literature on depression in cardiovascular patients, and this review has 
analyzed some of that literature and synthesized recommendations for providers in 
primary care practices with the purpose of standardizing routine screening for depression 
in cardiovascular patients in primary care. Based on the evidence, recommendations 
include screening for and treatment of depression in these patients, as well as 
recommendations for provider, staff, patient, and family education throughout the 
screening and treatment processes (Lichtman et al., 2008; Mavrides & Nemeroff, 2013; 
Agren et. al., 2014).  
With regard to screening tools, the PHQ-2 and PHQ-9 questionnaires are the most 
brief, sensitive, and specific depression screening tool for patients with cardiovascular 
disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). The PHQ-9 is based 
directly on DSM-IV diagnostic criteria for major depression, and this tool has shown to 
be valid and reliable after having been widely utilized in studies with cardiac patients 
(Stafford et al., 2007). Multiple safe treatment options exist for patients who test positive 
for depressive symptoms with SSRIs being shown as especially safe and effective in 
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patients with cardiovascular disease (Davidson, et al., 2010; Mavrides & Nemeroff, 
2013). Also, recommendations have been made for further research into this area of study 
in order to support standardized screening protocols that might facilitate improved 
processes for patients with depression with cardiovascular disease in all primary care 
settings (Huffman et. al., 2014). 
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Chapter 3 Methodology 
3.1 Introduction 
 According to the American Heart Association (2016), there is no gold-
standardized procedure for screening for depression in cardiovascular patients. Screening 
for depression varies greatly across specialties and practices, often leaving a gap for 
detection and treatment of depression in cardiac patients (McGuire et al., 2015). The 
purpose of this project is to determine the best screening depression tool and implement 
the tool for early detection of depression in primary care settings for patients with 
cardiovascular disease. The purpose of this chapter is to describe the design, sample, 
setting, depression screening tool, and procedures utilized in this project. 
 3.2 Design  
A descriptive pre-test and post-test survey design will be conducted to compare 
findings from two primary care settings, which use the Patient Health Questionnaire 
(PHQ) depression screening tool to screen for depression in cardiovascular patients. The 
PHQ is a multiple-choice self-report inventory used for screening and diagnosing 
depression.  It is copyrighted by Pfizer Inc. 
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3.3 Unit of Analysis 
The first unit of analysis will include the findings from an audit on 60 patient 
charts and the results of their depression screenings.  Demographic data that will be 
collected includes age, gender, and race of all the patients.  
The second unit of analyses will include data from the Patient Health 
Questionnaire (PHQ).  The tool is available in two forms, PHQ-2 and PHQ-9. The PHQ-
2 comprises the first two questions in the PHQ-9 questionnaire. As McGuire, et al., 
(2015) discusses, the PHQ-2 screening scale is the best brief screening instrument for use 
during a routine visit intake or annual physical examination survey. According to the 
American Psychological Association (2016), the PHQ-2 inquires about the degree to 
which an individual has experienced a depressed mood and anhedonia over the past two 
weeks. Its purpose is not to establish a final diagnosis or to monitor depression severity, 
but rather to screen for depression (APA, 2016). Patients who screen positive should be 
further evaluated with the PHQ-9 to determine whether they meet criteria for a depressive 
disorder (APA, 2016).   
           The third unit of analysis will include the providers’ demographic data who care 
for cardiovascular patients in primary care settings. The providers are employed in family 
practice settings located in the Pee Dee area of rural South Carolina. Demographic data 
includes one MD and one Family Nurse Practitioner in the first family practice and two 
MDs and one FNP in the second family practice. Provider gender, provider specialty, and 
provider length of time (years) in practice will be collected for each provider. Providers 
will also be asked if they have utilized the PHQ screening tool in practice previously. 
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3.4 Sample 
The sample includes 60 adult cardiovascular patients who present for primary 
care in two primary care settings in rural Pee Dee South Carolina. For the purpose of this 
project, a patient with “cardiovascular” disease will be defined as any patient who is 18 
years of age or older and has any or a combination of the following diagnoses: coronary 
artery disease, stroke, hypertension, congestive heart failure, arrhythmias, valvular heart 
disease, cardiomyopathy, myocardial infarction, and rheumatic heart disease. The 
primary care providers are adult primary care providers, including three physicians and 
two family nurse practitioners.  All providers are licensed by the state of South Carolina.  
3.5 Setting 
              The settings include two family practices in rural South Carolina in the Pee Dee 
area.  The family practices are comprehensive family practices open five days per week, 
with on-call after hour services.  These practices serve as the patient’s first point of entry 
into the health care system and as the continuing focal point for all needed health care 
services. The first practice sees an average of 38 patients per day, and the second practice 
sees an average of 51 patients per day.  
3.6 Outcomes to be measured 
The PHQ-9 is a nine-item self-report measure developed to diagnose the presence 
and severity of depression in primary care (Stafford, Hons, Berk, & Jackson, 2007). It is 
based directly on DSM-IV diagnostic criteria for major depression (Stafford, et al., 2007). 
It has the potential of being a dual-purpose instrument that, with the same nine items, can 
establish depressive disorder diagnoses using a categorical algorithm and grade the 
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depressive symptom severity (Stafford, et al., 2007). As a severity measure, the score on 
the PHQ-9 will range from 0 to 27 for each patient. The scale is scored as follows: 1-4 
(minimal depression), 5-9 (mild depression), 10-14 (moderate depression), 15-19 
(moderately severe depression), and 20-27 (severe depression) (Stafford, et al., 2007). 
In multiple studies, PHQ-9 scores greater than 10 have been found to have a 
sensitivity of 88% and a specificity of 88% for Major Depressive Disorder (APA, 2016). 
The PHQ questionnaires have been shown to be valid and reliable and have been widely 
utilized in studies with cardiac patients (Stafford, et al., 2007). The Mini International 
Neuropsychiatric Interview (MINI) was the criterion standard (Stafford, et al., 2007). In 
this study, scale reliability was calculated using Cronbach's α. Convergent validity was 
computed using Pearson's intercorrelations (Stafford, et al., 2007). The internal 
consistencies for the self-report questionnaire were excellent with Cronbach's α 
coefficient of 0.90 for the PHQ-9 (Stafford, et al., 2007). 
3.7 Framework/model of research: Stetler’s Model  
The Stetler model of Evidence-Based Practice (Appendix D) was chosen because 
it has long been known as a practitioner-oriented model which utilizes research findings 
in order to facilitate safe and effective evidence-based nursing practice (Melnyk & 
Fineout-Overholt, 2015).  There are five phases in the Stetler model. First, Stetler’s 
model will be utilized by ensuring the providers and practices are ready for the change 
and systematically conducting a search for relevant evidence (Melnyk & Fineout-
Overholt, 2015). Stetler’s second phase has been utilized to assess a body of evidence, 
summarize the evidence for quality and validity, and identify a need through the 
systematic collection of evidence (Melnyk & Fineout-Overholt, 2015).  Phase three will 
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be used to compare the responses from the survey and evaluate if the intervention 
combined with the guidelines proposed a change to current practice. The fourth phase of 
Stetler’s model will be used to demonstrate translation or application of the intervention, 
with the implementation of the PHQ-2 and PHQ-9 screening tools for patients with 
cardiovascular disease (Melnyk & Fineout-Overholt, 2015).  In phase five, evaluation of 
the plan to improve outcomes for patients with CVD who suffer from depression through 
the implementation of screening tools and follow-up screenings with appropriate 
treatment will be implemented and evaluated (Melnyk & Fineout-Overholt, 2015). 
3.8 Description of intervention 
 Depression screening is an essential part of the detection, treatment, and referral 
of patients with depressive disorders. The PHQ-2, comprising the first 2 items of the 
PHQ-9, inquires about the degree to which an individual has experienced depressed 
mood and anhedonia over the past two weeks. Its purpose is not to establish final 
diagnosis or to monitor depression severity, but rather to screen for depression. Patients 
who screen positive on the PHQ-2 should be further evaluated with the PHQ-9 to 
determine whether they meet criteria for a depressive disorder.  
According to McGuire et al., (2015), there continues to be a significant practice 
gap in relation to screening, referral, and treatment of depression in CVD patients (p. 
427). Although the American Heart Association recommends routine screening for 
depression in patients with cardiovascular disease, there are conflicting opinions among 
healthcare providers with regard to timing of screening and location of screening, 
especially in cardiology and primary care settings (Kronish, et al., 2012).  
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Prior to administering the PHQ screening tool to patients, the providers at both 
primary care practices will be given educational handouts that contain information 
regarding the PHQ-2 and PHQ-9 depression screening tools. These educational handouts 
will include the following: risk factors of depression in patients with cardiovascular 
disease, signs and symptoms of depression, directions for utilizing the PHQ tool, 
importance of educating patients and families regarding depression, and an algorithm for 
initiation of depression treatment and referral for those patients who test positive during 
screening.  
The providers will also have the opportunity to view a YouTube video describing 
the use and administration of PHQ screening for depression. The YouTube video is 
presented by Dr. Charles Porter and a Cardiology group in Kansas City on behalf of 
patients who have comorbid cardiovascular disease and depression. The video is 4 
minutes and 14 seconds in length, and the providers may easily view the video from 
home. The video may be accessed via the following URL: 
https://www.youtube.com/watch?v=DtQCp5350as. A sign in sheet will be provided at 
the offices for providers to sign once they complete the video. These additional resources 
will allow each provider equal opportunity to access significant information regarding 
depression screening in cardiovascular patients.  
3.9 Strategies to reduce barriers and increase supports 
The influential change participants in primary care will include practice 
administrators, board of directors, and primary care providers. In order for the 
implementation of these screenings to be successful, support of these influential 
participants must be obtained. A strategy that will increase support is to demonstrate the 
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ease of use and effectiveness of the short screening PHQ tools. This cost-effective and 
easy-to-use tool may be easily administered and has been shown to decrease morbidity 
and mortality in patients with cardiovascular disease, thereby reducing healthcare costs. 
The PHQ screening tools are a cost-effective, reliable, valid, and time-efficient approach 
to improving patients’ quality of life. The strategic process for implementing this 
intervention can be addressed with the most significant emphasis on improving quality of 
life for patients with cardiovascular disease.   
A potential barrier to successful implementation of routine depression screening is 
the issue of fidelity. Burns, Grove, and Gray (2013) describe fidelity as the consistent 
implementation of an intervention. Since part of the plan will involve other providers, it 
will be of utmost importance to ensure that an organized plan or protocol is in place so 
that each provider interacts with the patients in the same manner in relation to the project. 
The protocol for implementation of this screening tool will require that each patient has 
cardiovascular disease and is 18 years of age or older. The protocol will require that the 
first two questions of the tool (PHQ-2) be administered to the patient by the provider 
while the provider is in the room to examine the patient. If these two questions are 
positive, the provider will proceed by administering the remaining seven questions of the 
questionnaire. The protocol will then require that the provider score the patient’s 
depression according to the scale that is provided with the PHQ tool. If the patient is 
tested positive for depression, the provider will be asked to document in chart the 
implemented treatment plan, follow up, education, and any referrals that are made. This 
protocol will be discussed with each provider and will be given as a handout prior to 
implementation of the screening tool. 
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  If the screening tool is to be implemented into the EMR for future implementation 
of this tool into project, this may limit the feasibility utilization of the screening tool since 
EMRs have been traditionally difficult to change or manipulate. There has also been 
consideration concerning administration of the PHQ-2 and PHQ-9 screenings on paper 
and having them scanned into the EMR since the providers are still using some paper 
forms in conjunction with EMR documentation. As Melnyk and Fineout-Overholt (2015) 
discuss, many times it takes more time to carry out a study than is projected in the 
beginning of the project. Time is also a possible limit to administration of screenings and 
collection of data, but it is hopeful that the project may be undertaken as a 3-month 
review of the initial screenings and initial follow up visits without difficulty. 
3.10 Instruments 
 Provider demographic information will be collected during a scheduled office 
visit and entered into Microsoft Excel for analysis comparison using the Data Analysis 
Tool. Similarly, during the chart audits, each patient’s demographic data will be collected 
and entered into the Data Analysis Tool in Microsoft Excel. Demographic data for 
patients will include age, gender, and race. The PHQ screening tool will be administered 
to the patients by the provider. The PHQ screening tool will be administered on paper and 
scanned into the electronic medical record for review at the end of the 3-month period.  
3.11 Procedure  
Step one will consist of training the providers on the use of the tool and 
administration of the tool. The PHQ depression screening tool will be administered by the 
providers to the patients in the privacy of the examining room if the patient meets 
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appropriate criteria and agrees to the screening. Patients must be 18 years or older and 
must have a documented history of cardiovascular disease without a documented history 
of depression. The PHQ-2 will be answered, which consists of the first two questions of 
the scale. If positive, the remaining seven questions (PHQ-9) will be administered. 
Copies of the PHQ tool will be given to both practices. Completed tools will be scanned 
into the EMR in each respective patient’s chart. If the patient self-identifies that they are 
moderately or severely depressed based on a score of 10 or higher on the PHQ scale, then 
the patient is referred for further assessment and intervention. 
After the University of South Carolina Institutional Review Board (IRB) approves 
the study, the quality improvement project will commence. Educational handouts 
regarding the importance of depression screening in cardiovascular patients and regarding 
the use of PHQ screening tools will be given to the providers at enrollment into this 
project. The handouts will contain information on signs and symptoms of depression that 
have been commonly encountered by cardiac patients. The handouts will identify the 
importance of educating patients and family members regarding the seriousness of 
depression and the availability of treatment. Providers will be provided with email and 
phone number in order to ask any questions regarding implementation of the screening 
tool for this project. 
Three months after implementation of the PHQ screening tool, 60 charts will be 
reviewed, which will include a total of 30 charts from each practice.  Data obtained from 
the PHQ tools will be migrated into Microsoft Excel’s for statistical and descriptive 
analysis of the Likert scale.  Each question (Appendix C) will be calculated by the mode.  
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The mode of the data is the value which appears most frequently as mentioned 
previously.  This will be placed in a table and illustrated in a bar graph format. 
3.12 Protection of Human Subjects 
The Collaborative Institutional Training Initiative (CITI) course on protection of 
human subjects will be completed by the investigator for the University of South 
Carolina prior to data collection. Two members of the committee will provide scientific 
review of the proposal. Since this project includes research of medical records, review 
and approval by the University of South Carolina’s IRB will be required. IRB approval 
for this project will be sought prior to any involvement of patient information. The 
investigator is an employee of the healthcare system in which the practices are included 
and has access to the electronic medical records. 
Once the committee and IRB have reviewed and approved the project, the 
investigator will begin data collection. Only essential patient data for the project will be 
retrieved. Data that will be retrieved from each chart are as follows: age of the patient, 
race, gender, cardiovascular diagnoses, existence of previous psychiatric diagnoses, 
PHQ-2 and PHQ-9 screening results, subsequent initiation of depression treatment and 
counseling by the providers, and initiation of psychiatric referrals if needed. 
All data which is collected will be saved in the investigator’s computer in a 
password protected spreadsheet. The computer to be utilized is password protected, and 
there will be no record included to identify any of the subjects. The patients will be 
assigned a number as a patient identifier, and their names will not be used. In order to 
protect patient information, all patient information will be collected, encrypted, and 
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stored on a flashdrive. No tracers will be linked to patient health records in order to 
protect patient anonymity. 
3.13 Data Analysis Methods  
PHQ screening tool results of 60 patients with cardiovascular disease will be 
collected during chart review and entered into Microsoft Excel. The Data Analysis tool in 
Excel will be utilized to graphically display the results of the PHQ screenings. Microsoft 
Excel spreadsheets and graphs will also be utilized for collection of the providers’ 
demographic data. Excel Data Analysis Correlation function will be utilized to compare 
provider usage of the tool between the two practices, which will allow for inferences to 
be made regarding provider demographic data and use of PHQ screening tools between 
the two practices.  
Once the survey data is entered into the Excel spreadsheet and the identifiers 
removed, the data will be reviewed and organized in collaboration with a University of 
South Carolina statistician. Data analyses will include both descriptive and inferential 
statistics using the Data Analysis tool in Excel.  
3.14 Chapter Summary 
Despite poor outcomes, comorbid cardiovascular disease and depression remain 
poorly recognized and treated. Primary care providers are called upon to improve their 
recognition of depressive symptoms in their patients and assure appropriate treatment is 
initiated per current guidelines. At new patient and routine follow up visits, the PHQ-2 
and PHQ-9 screening tools should be implemented for each patient who has 
cardiovascular disease. This active approach to delivering quality care and screening for 
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prevention of complications from depression can potentially improve quality measures 
and outcomes in management of patients with cardiovascular disease. 
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Chapter 4 Results 
4.1 Introduction 
 According to Lichtman, et al., (2008), there is a high prevalence of depression in 
patients with cardiovascular disease. Thus, the American Heart Association (2016) has 
recommended routine screening for depression. In this DNP quality improvement project, 
a descriptive pre-test and post-test survey design was conducted to compare findings 
from two primary care settings that implemented the use of the brief and efficient Patient 
Health Questionnaire (PHQ) depression screening tool to screen for depression in 
cardiovascular patients. The purpose of this chapter is to present the findings with a 
discussion. 
4.2 Description of Sample 
 
           Out of the sixty patient charts which were audited, fifty-one (response rate was 
85%) patient health questionnaire (PHQ) depression screening tool surveys were 
completed. These questions were administered to the patients by five primary care 
providers in two primary care practices in the Pee Dee area over a two-month period. The 
primary care providers are adult primary care providers, including three physicians and 
two family nurse practitioners.  All providers are licensed by the state of South Carolina.  
            The patients were screened for depression through use of the PHQ-2 and PHQ-9 
depression screening tools. Thirty charts were initially audited from each practice. Five 
patients canceled their appointments prior to screening, three patients did not show for 
their appointments, and one patient declined to answer the screening survey questions. 
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There were twenty-three patients who answered the screening tool survey questions from 
the first practice, and twenty-eight patients responded to the survey in the second primary 
care practice. The final sample (n = 51) was comprised of adult patients, ages ranging 
from 35-78, who had a pre-existing cardiovascular diagnosis but no history of diagnosed 
depression. Cardiovascular diagnoses for these patients included hypertension, coronary 
artery disease, history of myocardial infarction, congestive heart failure, and stroke.  
4.3 Analysis of Research Questions 
 
           Table 4.1 depicts the frequency distribution of the patients’ responses to the 
depression screening tool survey from both practices combined. Microsoft Excel’s 
FREQUENCY function for data analysis was utilized to calculate frequency 
distributions. According to the screening tool results, 29% (n=15) of the sample 
population had little interest or pleasure in doing things over the past 2 weeks. Results 
also indicated that the patients felt down or depressed over the 2 weeks prior to screening. 
Following the initial two questions of the surveys, trouble sleeping (27%) was the next 
most common symptom identified. (Table 4.1). 
Table 4.2 depicts the comparison of patients’ responses between the two primary 
care practices. Responses were similar from both practices. None of the sample had a 
formalized diagnosis of depression or treatment of depression prior to implementation of 
this screening tool. Of note, Practice 1 had a higher rate of positive responses to trouble 
concentrating, moving or speaking slowly, and restlessness. However, these patients from 
Practice 1 also had prior diagnoses of attention deficit disorders. The patients were not 
currently receiving treatment for attention deficit disorders (Table 4.2). 
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Table 4.1 PHQ Screening Tool Survey Frequency Distributions (Both Practices) 
 
Over the past 2 weeks, have you been bothered 
by any of the following? 
 
Yes 
 
 
% 
No 
 
 
% 
Little interest or pleasure in doing things 29 71 
Feeling down, depressed, or hopeless   29 71 
Trouble falling asleep, staying asleep, or sleeping 
too much 
27 - 
Feeling tired or having little energy 23 - 
Poor appetite or overeating 18 - 
Feeling bad about yourself, that you are a failure, 
or that you have let yourself or your family down 
20 - 
Trouble concentrating on activities such as 
reading the newspaper or watching television 
22 - 
Moving or speaking so slowly that other people 
could have noticed, or being so fidgety or restless 
that you have been moving around a lot more 
than usual 
12 - 
Thinking that you would be better off dead or that 
you want to hurt yourself in some way 
4 - 
 
Table 4.3 depicts the t-Test calculations which were performed utilizing the Data 
Analysis TookPak with t-Test function in Microsoft Excel. Results showed that there 
were no statistically significant differences between the practices for patients reporting 
depression symptoms using the PHQ.  Patients with cardiovascular disease reported 
depression symptoms across the board in both practices (Table 4.3.) 
Table 4.4 depicts the prevalence of each category of depression severity from 
both practices as diagnosed from utilization of the PHQ screening tool. Providers were 
able to make diagnosis with severity of depression using the results of the PHQ 
screenings. The majority of patients in each practice scored 10-19 on the PHQ scale 
which indicated that these patients were in the severity categories of “moderate” 
depression or “moderately severe” depression per the PHQ scoring card. (Table 4.4). 
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Table 4.2 Comparison of PHQ Results Between Two Primary Care Practices 
Over the past 2 weeks, have you been 
bothered by any of the following? 
 
Practice 1 
“Yes” Responses 
 
% 
Practice 2 
“Yes” Responses 
 
% 
Little interest or pleasure in doing things 26 32 
Feeling down, depressed, or hopeless   26 32 
Trouble falling asleep, staying asleep, or 
sleeping too much 
26 29 
Feeling tired or having little energy 21 25 
Poor appetite or overeating 17 18 
Feeling bad about yourself, that you are a 
failure, or that you have let yourself or your 
family down 
22 18 
Trouble concentrating on activities such as 
reading the newspaper or watching television 
26 18 
Moving or speaking so slowly that other 
people could have noticed, or being so fidgety 
or restless that you have been moving around 
a lot more than usual 
17 7 
Thinking that you would be better off dead or 
that you want to hurt yourself in some way 
4 4 
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Table 4.3 t-Test Values of Comparison of PHQ Results Between Practices 
t-Test: Two-Sample Assuming Equal Variances  
   
  Practice 1 Practice 2 
Mean 20.55555556 20.33333333 
Variance 52.52777778 103.75 
Observations 9 9 
Pooled Variance 78.13888889  
Hypothesized Mean Difference 0  
df 16  
t Stat 0.053328593  
P(T<=t) one-tail 0.479065139  
t Critical one-tail 1.745883676  
P(T<=t) two-tail 0.958130278  
t Critical two-tail 2.119905299   
Table 4.4 Depression Severity in Patients with CVD as 
Compared Between Two Primary Care Practices 
Depression Severity  Practice 1 
% 
Practice 2 
% 
Mild Depression 33 22 
Moderate Depression 50 33 
Moderately Severe Depression 0 33 
Severe Depression 17 11 
 
Table 4.5 compares the implementation results of the two practices for the 
cardiovascular patients who tested positive for depression. Consistent with current 
literature, the most commonly chosen antidepressants for the patients were the SSRIs 
sertraline and escitalopram (Davidson, et al., 2010). SSRIs were chosen most frequently 
(50% of patients with positive diagnosis) above all other antidepressants in Practice 1 and 
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in Practice 2 (67%). Bupropion was the second choice after SSRIs in both practices. 
There was one patient in each practice who answered “yes” to the question regarding 
thoughts of self-harm, and these two patients were referred immediately for psychiatric 
evaluation and counseling.  
Table 4.5 Comparison of Depression Treatment Interventions Between Two 
Practices 
Interventions utilized by the primary care 
providers for treatment of depression 
Practice 1 
 
% 
Practice 2 
 
% 
Initiation of SSRI (sertraline, escitalopram, 
citalopram) 
50 67 
Initiation of SNRI (venlafaxine) 17 11 
Initiation of Bupropion 33 22 
Initiation of Tricyclic Antidepressants  0 0 
Depression Counseling 100 100 
Referral to Psychiatry 17 11 
Table 4.6 depicts the t-Test calculations which were performed utilizing the Data 
Analysis TookPak with the t-Test function in Microsoft Excel. The p-value 
(0.964134897) for these results was not statistically significant. The providers in both 
practices utilized similar treatment approaches for these patients based on current 
evidence-based depression treatment recommendations and guidelines. (Table 4.6.) 
4.4 Conclusion 
 
Frequency distributions were calculated for PHQ depression screening survey 
results for each question in order to note the frequency of depressive symptoms in this 
sample of patients with cardiovascular disease. Patients who answered “yes” to the initial 
two screening questions were asked the remaining seven questions per the screening tool 
guidelines. Results were then compared between the two practices to note differences in 
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patients’ responses from each practice.  
Table 4.6 t-Test Values of Comparison of Treatment Choices Between Practices 
t-Test: Two-Sample Assuming Equal Variances  
   
  Practice 1 Practice 2 
Mean 36.16666667 35.16666667 
Variance 1263.766667 1558.966667 
Observations 6 6 
Pooled Variance 1411.366667  
Hypothesized Mean Difference 0  
df 10  
t Stat 0.046104222  
P(T<=t) one-tail 0.482067449  
t Critical one-tail 1.812461123  
P(T<=t) two-tail 0.964134897  
t Critical two-tail 2.228138852   
 
After frequency distributions were calculated, it was noted that 29% of the sample 
population had depressive symptoms. This data is consistent with the evidence-based 
literature that demonstrates that patients with cardiovascular disease are at high risk for 
depression and should be routinely screened for depression in their primary care homes 
as recommended by the American Heart Association (2016). Each of these patients 
(n=15) who screened positive for depression was started on treatment for depression at 
the time of the initial depression screening visit. 
During the post-test portion of the study, the fifty-one charts were reviewed after 
screening and implementation of treatment measures by the providers in order to compare 
the chosen treatment options in both practices. All of the providers documented the 
utilization of depression counseling during the initial visits, including the use of 
educational handouts regarding depression printed from the electronic medical record. 
SSRIs were the most frequently utilized Pharmacotherapy treatment choice in each 
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practice, followed by the use of Bupropion. Follow up appointments ranged from 1-2 
weeks dependent upon other comorbid conditions and severity of depressive symptoms.  
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Chapter 5 Discussion 
5.1 Introduction 
Throughout the literature review and at completion of the DNP quality 
improvement project, recommendations have been identified to assist primary care 
providers in improving the quality and timeliness of care delivered to cardiovascular 
patients who are suffering from depression. Timely screening, detection, and treatment of 
depression in patients with cardiovascular disease may help to improve quality of life and 
increase overall survival for these patients (Sin, et al., 2014). The purpose of this chapter 
is to discuss recommendations for practice, education, research, and health policy based 
on the findings of this project and evidence-based literature. 
5.2 Recommendations for Practice  
 
According to the quality improvement project and consistent with the literature, 
patients with cardiovascular disease are at high risk for depression and should be 
routinely screened to improve quality of life and patient outcomes (McGuire, et al., 2015; 
Mavrides & Nemeroff, 2013). Nearly one third of the sample screened positive for 
depression (DNP Project, Ballentine, 2017). Through an evaluation of the available 
depression screening tools, synthesis of the literature revealed that the PHQ-2 and PHQ-9 
tools are the most brief, sensitive, and specific depression screening tool for patients with 
cardiovascular disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). In this 
quality improvement project, the PHQ-9 screening tool was found to have a sensitivity of 
90% and specificity of 90% (DNP Project, Ballentine, 2017). These results are similar to 
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findings in multiple studies where PHQ-9 scores greater than 10 have been found to have 
a sensitivity of 88% and a specificity of 88% for Major Depressive Disorder (APA, 2016; 
Stafford, et al., 2007).  
Findings from the quality improvement project underscored the need for primary 
care providers to utilize the patient health questionnaire (PHQ) screening tool as the 
standard for screening in patients with cardiovascular disease due to the incidence of 
depression in cardiovascular patients and the tool’s efficacy and ease of use. The PHQ 
screening tools are a cost-effective, reliable, valid, and time-efficient approach to 
improving patients’ quality of life (McGuire, et al., 2015; Ceccarini, et al., 2014). In 
patients with positive depression scores, the provider should review the answers with the 
patient, and treatment options should be discussed with the patient.  
Also, consistent with the literature, providers in the quality improvement project 
chose SSRIs most frequently in the treatment of their patients who screened positive for 
depression. There is considerable evidence from randomized controlled clinical trials that 
antidepressants, especially SSRIs, are safe in the treatment of major depression in 
patients with CVD (Mavrides & Nemeroff, 2013). Researchers have concluded that 
frequent and timely treatment initiation by primary care providers, along with increased 
patient self-monitoring, leads to improved control of depression and cardiovascular 
disease (Mavrides & Nemeroff, 2013; Kronish, et al., 2012; McGuire, et al., 2015). 
Evidence also suggests that depressed patients who are not responsive to treatment for 
depression may be at greater risk for adverse cardiac events, but aggressive cardiologic 
care may help mitigate this increased risk (Lichtman et al., 2008). Depressed patients 
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may also require additional clinical management to ensure compliance with cardiac 
treatment regimens and to promote lifestyle behavior change. 
Providers must be prepared to refer depressed patients when necessary. During 
the quality improvement project, one patient from each practice stated that they recently 
had thoughts of self-harm, and these patients were promptly referred for further 
psychiatric evaluation and treatment. Appropriate follow up appointments should be 
scheduled for all patients with depressive symptoms in order to monitor progress and 
responses to treatment. 
5.3 Recommendations for Education 
Prior to implementation of the quality improvement screening tool, providers and 
nursing staff were educated on the use of the PHQ tool. Formal and clear procedures, 
mechanisms, regular case reviews, and peer staff development need to be in place in 
order to sustain a successful screening program and offer an environment which aids in 
bringing about the best outcome for the patient dealing with depression. Depression 
screening in primary care should be included in continuing medical education 
requirements for providers working in the primary care setting (Agren et. al., 2014; 
Lichtman et al., 2008; Mavrides & Nemeroff, 2013). 
Providers and staff should educate patients and families on the potential impacts 
of depression on their health and quality of life. Patients and families should also be 
educated on the importance of compliance with treatment regimens in the successful 
treatment of depression. During this quality improvement project, providers documented 
counseling the patients with depression 100% of the time. 
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 Psychoeducational counseling and intervention have been found to reduce 
anxiety and depression in patients with cardiovascular disease, and educational 
interventions increase patient and family satisfaction (Agren et. al., 2014). When the 
families and the patients are well-informed, there is a basis for fruitful and effective 
communication between them and the healthcare professionals leading to increased 
compliance to treatment regimens and overall better outcomes (Agren et al., 2014). 
5.4 Recommendations for Research 
 Adequately powered and randomized clinical trials remain necessary to develop 
refinements in screening tools and collaborative care models which can lead to even 
greater improvements in mental health and function in patients with CVD (Huffman, et 
al., 2014). Researchers suggest that further research efforts to address increased mortality 
in depressed patients with cardiovascular illnesses should focus on processes that impact 
cardiac functional status (Huffman, et al., 2014).  Additional research is needed to 
properly characterize evidence-based care of patients with comorbid depression and 
cardiovascular disease. Also, more trials are needed before the recognition and treatment 
of depression becomes part of the routine clinical care of patients with cardiovascular 
disease due to several factors including time constraints in primary care practice and lack 
of standardized depression screening across specialties.  
Randomized controlled trials are warranted to examine existing and newer 
depression treatment strategies in patients with cardiovascular disease. In one clinical 
trial, sertraline led to improvement in depressive symptoms without any increased risk of 
adverse cardiac events (Shapiro, et al., 1999). However, data on potential harms such as 
adverse effects of antidepressants in patients with cardiovascular disease are quite 
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limited. The new RCTs should be designed with extended periods of follow-up that 
enable more complete ascertainment of side effects and potential harm of antidepressant 
use. More trials such as these are needed to examine the effect of SSRIs and other 
available treatments on mortality and cardiac events. 
5.5 Recommendations for Health Policy 
According to Healthy People 2020, the burden of mental illness in the United 
States is among the highest of all diseases, and mental disorders are among the most 
common causes of disability (USDHHS, 2014). The Healthy People 2020 goal is to 
“improve mental health through prevention and by ensuring access to appropriate, quality 
mental health services” (2014). The U.S. Preventive Services Task Force (2010) 
recommends screening adults for depression when staff-assisted depression care supports 
are in place to assure accurate diagnosis, effective treatment, and follow-up. Persons at 
increased risk of depression are considered at risk throughout their lifetime, and groups at 
increased risk include persons with chronic medical diseases such as cardiovascular 
disease (USPSTF, 2010). Chronically ill Medicare beneficiaries with accompanying 
depression have significantly higher health care costs than those with chronic diseases 
alone (Unützer, 2009).  
Several recent changes in healthcare policy have promoted access to mental 
health for the population; however, there continues to be a significant gap in care for 
people with mental health disorders in the United States (CDC, 2011). These changes 
include detection and treatment of depression in patients with comorbid chronic illnesses 
and older adults. The 2005 White House Conference on Aging adopted a resolution to 
improve recognition, assessment, and treatment of mental illness and depression among 
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older Americans (CDC, 2011; WHCOA, 2005). Medicare Part B covers one depression 
screening per year, and these screenings must be administered in a primary care setting 
that can provide follow-up treatment (CMS, 2017).  
Limited access to care continues to be a problem for people with mental health 
disorders in the United States. Barriers to care include mental healthcare provider 
shortages. Although healthcare reform has reduced the rates of uninsured adults, many 
adults in the United States remain uninsured which presents another barrier to care. It is 
important to support all levels of government to adopt mental health policies and to 
integrate mental health policy into public health policy and general social policy. 
As the Federal Government continues to implement the health reform legislation, 
it will bring attention to providing services for individuals with mental health disorders, 
including new opportunities for access to and coverage for treatment and prevention 
services (USDHHS, 2014). It would be beneficial to ensure mental health is included in 
generic health reforms that are occurring, such as development of health information 
systems, quality improvement initiatives, basic training and continuing education 
standards, and accreditation procedures. Health policy should promote population-level 
depression screening programs based on the literature and current screening guidelines. 
Mental health reform policies should also seek to improve the current grant program 
related to integration of mental health and primary care with a new approach to drive 
significant reforms that improve care and health outcomes for patients with mental health 
disorders. Primacy care providers should have incentives to screen routinely per current 
guidelines such as those of the USPSTF (2010). 
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5.6 Limitations 
With regard to limitations of the quality improvement project, the sample size was 
relatively small (n=51), and this may increase threats to external validity of the project. 
The patients were chosen by appointment date, which increased randomization, thereby 
minimizing threats to the internal validity of the project. The results of the screening 
surveys and implemented interventions were similar between both practices, which 
increases the generalizability of the results and recommendations from the project. The 
length of time for the project was a significant limitation to this study, allotting the 
providers only 2 months to implement the depression screening tool and treatment plan 
for the patients. 
5.7 Conclusion 
Despite the devastating consequences, comorbid cardiovascular disease and 
depression remain poorly recognized and treated (Paz-Filho, 2010; Lichtman et al., 
2008). Primary care providers are called upon to improve their recognition of depression 
in their patients and assure prompt treatment is initiated in these patients (Lichtman et al., 
2008). There is a vast literature on depression in cardiovascular patients, and 
recommendations have been made for providers in primary care practices with the 
purpose of standardizing routine screening for depression in cardiovascular patients in 
primary care. Based on the evidence and findings of this project, recommendations 
include screening for and treatment of depression in these patients, as well as 
recommendations for provider, staff, patient, and family education throughout the 
screening and treatment processes (Lichtman et al., 2008; Mavrides & Nemeroff, 2013; 
Agren et. al., 2014).  
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With regard to screening tools, the PHQ-2 and PHQ-9 questionnaires are the most 
brief, sensitive, and specific depression screening tool for patients with cardiovascular 
disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). The PHQ-9 is based 
directly on DSM-IV diagnostic criteria for major depression, and this tool has shown to 
be valid and reliable after having been widely utilized in studies with cardiac patients 
(Stafford et al., 2007).  
Multiple safe treatment options exist for patients who test positive for depressive 
symptoms with SSRIs being shown as especially safe and effective in patients with 
cardiovascular disease (Davidson, et al., 2010; Mavrides & Nemeroff, 2013). Also, 
recommendations have been made for further research into this area of study in order to 
support standardized screening protocols that might facilitate improved processes for 
patients with depression with cardiovascular disease in all primary care settings 
(Huffman et. al., 2014).
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Appendix A: Evidence Table 
Brief Reference, Type 
of study, Quality rating 
Methods Threats to validity/ reliability Findings Conclusions 
Mavrides, N. & 
Nemeroff, C. (2013). 
  
Treatment of depression 
in cardiovascular 
disease. Depression and 
Anxiety, 30: 328-341. 
doi: 10.1002/da.22051. 
 
Systematic Review of 
RCTs 
 
Level I Evidence 
 
Quality Rating: A – 
High Quality 
Systematic Review of 61 
randomized controlled 
clinical trials. PubMed and 
PsycINFO databases were 
searched through July 2012. 
No trials were excluded, and 
the studies included were 
primarily from North 
America and Europe. The 
search was completed with 
key words of antidepressants, 
CVD, coronary artery 
syndrome, SSRIs, depression, 
treatment of depression, post-
MI, major depression, and 
cardiac disease. 
Internal Validity: The studies 
contained in this review are 
randomized control clinical trials, 
and this helps to minimize threats to 
internal validity. The authors stated 
that they limited search results to the 
English language. By limiting to 
English only, the researchers risk 
biasing the amount of research they 
may find with regard to their 
research topic.  
 
External Validity: The number of 
studies reviewed is 61, which should 
help to limit threats to external 
validity. The results were consistent 
across all studies increasing the 
generalizability of the results to the 
general population.  
 
Reliability: The authors displayed 
their results of all utilized clinical 
trials in an evidence table, and 
discussed odds ratios (OR), effect 
A total of 61 articles and 
book chapters were 
included. There is strong 
evidence for a bidirectional 
association between 
depression and CVD. 
Short-term treatment of 
depression with TCAs is 
relatively safe in patients 
with ischemic heart disease, 
heart failure, or previous 
MI. In general, the SSRIs 
are safe and probably 
effective in treating 
depression in patients with 
ischemic heart disease. 
There is 
considerable 
evidence from 
these randomized 
controlled clinical 
trials that 
antidepressants, 
especially SSRIs, 
are safe in the 
treatment of major 
depression in 
patients with CVD. 
Although efficacy 
has been 
demonstrated in 
some, but not all, 
trials for both 
antidepressants 
and certain 
psychotherapies, 
large, well-
powered trials are 
urgently needed. 
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sizes, and confidence intervals (CI) 
for the trials. The researchers 
compared the results of each study, 
which limits threats to reliability in 
this review.  
Peters, R., Pinto, E., 
Beckett, N., Swift, C., 
Potter, J., McCormack, 
T., … Bulpitt, C. (2010).  
 
Association of 
depression with 
subsequent mortality, 
cardiovascular morbidity 
and incident dementia in 
people aged 80 and over 
and suffering from 
hypertension. Data from 
the Hypertension in the 
Very Elderly Trial 
(HYVET). Age and 
Ageing, 39: 439-445. 
doi: 
10.1093/ageing/afq042. 
 
Randomized Control 
Trial 
Double-blind RCT of 
2,656 participants. 
The HYVET was a 
randomized double-
blind, placebo-
controlled trial and 
employed an 
antihypertensive 
treatment regimen of 
indapamide sustained 
release 1.5 mg with 
the optional addition 
of perindopril 2–4 
mg. Ethical and 
regulatory approvals 
were obtained prior 
to data collection. 
Depression scores 
were collected using 
the 15-item GDS 
administered as part 
of a Quality of Life 
(QoL) questionnaire 
at baseline and 
annually thereafter. 
Internal Validity: This was a double-blind 
RCT; therefore, the subjects were randomly 
assigned to experimental and control groups, 
and the subjects and providers were kept 
blind to the study group. Double-blinding 
helps to significantly minimize threats to 
internal validity by reducing selection bias 
(Dearholt & Dang, 2012). 
 
External Validity: This was a large study of 
2,656 participants, and this minimizes threats 
to validity. The subjects in each of the 
groups were similar with regard to 
demographic and baseline clinical variables, 
which makes the results more generalizable. 
Baseline demographics were clearly 
displayed in a table to complement the 
discussion in the article. Although 
participants were unable to enter the study if 
they required nursing care, the researchers 
did not collect rigorous information about 
activities of daily living, disability levels or 
maintenance of social networks, 
socioeconomic status or activity level. 
The researchers found that 
a GDS score of ≥6 was 
associated with an 
increased risk of all-cause 
and cardiovascular 
mortality and 
cardiovascular morbidity. 
Mood was found to be 
worse in those who 
previously had a cardiac 
event.  GDS score ≥6 was 
associated with increased 
risks of all-cause (HR 1.8, 
95% CI 1.4–2.3) and 
cardiovascular mortality 
(HR 2.10, 95% CI 1.5–3.0), 
all stroke (HR 1.8, 95% CI 
1.2–2.8) and all 
cardiovascular events (HR 
1.6, 95% CI 1.2–2.1). Risk 
of incident dementia also 
tended to be increased (HR 
1.28, 95% CI 0.95–1.73). 
Depressed mood is 
common in older 
people with 
hypertension. 
Higher depression 
scores were 
associated with an 
increased risk of a 
subsequent 
cardiovascular 
event, mortality 
and possibly 
dementia. The 
researchers suggest 
that further studies 
would require 
replication and 
exclusion of some 
alternative 
possibilities (such 
as following up a 
population known 
to be free of 
vascular disease or 
disability at 
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Level I Evidence 
 
Quality Rating: A – 
High Quality 
Therefore, there is the potential for 
uncontrolled confounding from unmeasured 
factors. This limits generalizability and 
presents possible threats to validity.  
 
Reliability: Hazard ratios (HR) and 
confidence intervals (CI) were discussed in-
depth, along with p-values. The treatment 
effect was large (level of significance), and 
the treatment is precise (CI). The large 
sample also minimizes threats to reliability. 
All results were clearly displayed in tabular 
form. 
baseline, or 
carefully 
controlling for the 
confounding effect 
of disability) 
before testing in an 
intervention trial. 
Huffman, J.C., 
Mastromauro, C. A., 
Beach, S. R., Celano, C. 
M., DuBois, C. M., 
Healy, B. C., …  
Januzzi, J. L. (2014). 
 
Collaborative care for 
depression and anxiety 
disorders in patients 
with recent cardiac 
events: The management 
of sadness and anxiety in 
cardiology (MOSAIC) 
randomized clinical trial. 
This is a single-blind 
randomized clinical 
trial, with study 
assessors blind to 
group assignment, 
from September 2010 
through July 2013 of 
183 patients admitted 
to inpatient cardiac 
units in an urban 
academic general 
hospital for acute 
coronary syndrome, 
arrhythmia, or heart 
failure and found to 
have clinical 
Internal Validity: This is a single-blind study 
with randomized assignment to the 
experimental and control groups. Study 
assessors were kept blind to the study group. 
Baseline sociodemographic and medical data 
were collected from the electronic medical 
record by blinded study staff and from 
patients prior to randomization.  
External Validity: Unfortunately, this study 
was not powered by an appropriate sample 
size, which increases the threat to external 
validity. The internal and external validity of 
the findings are strengthened by concurrent 
identification and management of multiple 
psychiatric conditions, inclusion of patients 
with multiple cardiac diagnoses to include a 
substantial proportion of patients admitted to 
Patients in the intervention 
group were found to have 
improvements in depressive 
symptoms and general 
functioning as compared to 
the control group at the end 
of the 24-week period. 
Patients randomized to CC 
had significantly greater 
estimated mean 
improvements in SF-12 
MCS at 24 weeks (11.21 
points [from 34.21 to 
45.42] in the CC group vs 
5.53 points [from 36.30 to 
41.83] in the control group; 
Collaborative care 
(CC) models for 
mental health 
conditions use 
nonphysician care 
managers (CMs) to 
systematically 
identify disorders, 
perform 
longitudinal 
assessments, and 
coordinate stepped 
treatment 
recommendations 
between mental 
health specialists 
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JAMA Internal 
Medicine, 174(6): 927-
935. 
 
Randomized Control 
Trial 
 
Level I Evidence 
 
Quality Rating: B – 
Good Quality 
depression, 
generalized anxiety 
disorder, or panic 
disorder on structured 
assessment. In this 
study, 92 patients 
were randomized to 
the intervention 
group and 91 to the 
control group (usual 
care group). 
a typical cardiac unit, use of patient 
preference in treatment, inclusion of patients 
(10%) who declined treatment as part of the 
intent-to-treat design, and centralized post-
discharge care management by telephone. 
Reliability: Results were displayed in tabular 
form. Confidence intervals and effect sizes 
were discussed by the researchers. The effect 
sizes of the intervention on mental quality of 
life, depression, and function were moderate 
(0.34 to 0.61), and the effect size on 
depression (0.45) is at the upper end of the 
range seen in typical collaborative care 
depression interventions. These results add to 
the reliability of the study and minimize 
threats. 
estimated mean difference, 
5.68 points [95% CI, 2.14-
9.22]; P =  .002; effect size, 
0.61). Patients receiving 
CC also had significant 
improvements in depressive 
symptoms and general 
functioning, and higher 
rates of treatment of a 
mental health disorder; 
anxiety scores, rates of 
disorder response, and 
adherence did not differ 
between groups. 
and primary 
medical providers. 
Collaborative care 
and related care 
management 
interventions for 
depression have 
improved 
treatment and 
outcomes in a 
variety of 
populations, 
including patients 
with CVD.  
Adequately 
powered and 
randomized trials 
remain necessary 
to determine 
whether 
refinements to this 
model can lead to 
even greater 
improvements in 
mental health and 
function.   
Davidson, K. W., 
Rieckmann, N., 
Clemow, L., Schwartz, 
J. E., Shimbo, D., 
A 3-month 
observation period to 
identify patients with 
ACS and persistent 
Internal Validity: This was a randomized 
study, which minimizes threats to internal 
validity. It was a single-blind trial in which 
patients were not blinded to their treatment 
At the end of the trial, the 
proportion of patients who 
were satisfied with their 
depression care was higher 
Enhanced 
depression care for 
patients with ACS 
was associated 
  
 
7
7
 
Medina, V., … Burg, M. 
M., (2010). 
 
Enhanced depression 
care for patients with 
acute coronary 
syndrome and persistent 
depressive symptoms: 
coronary psychosocial 
evaluation studies 
randomized controlled 
trial. Archives of 
Internal Medicine, 
170(7):600–608. 
doi:10.1001/archinternm
ed.2010.29. 
 
Randomized Controlled 
Trial 
 
Level I Evidence 
 
Quality Rating: B – 
Good Quality 
depressive symptoms 
was followed by a 6-
month single-blind 
randomized 
controlled trial. From 
January 1, 2005, 
through 
February 29, 2008, 
237 patients with 
ACS from 5 hospitals 
were enrolled, 
including 157 
persistently depressed 
patients randomized 
to intervention (initial 
patient preference for 
problem-solving 
therapy and/or 
pharmacotherapy, 
then a stepped-care 
approach; 80 
patients) or usual care 
(77 patients) and 80 
non-depressed 
patients who 
underwent 
observational 
evaluation. 
status for ethical reasons; however, outcome 
assessors were blinded. 
 
External Validity:  The patients selected for 
this trial did not include all patients with 
ACS. Researchers excluded those with 
cognitive impairments, other life-threatening 
conditions, and, most importantly, other 
psychiatric conditions such as alcohol or 
other drug dependence and bipolar disorder. 
Because these comorbid conditions are 
highly prevalent in depressed patients, the 
findings may not be applicable to all patients 
with ACS and depressive symptoms. This 
limits generalizability.  
 
Reliability: The researchers discussed odds 
ratios (OR), confidence intervals (CI), and 
levels of significance for their findings. They 
discussed the treatment effect and 
preciseness of the intervention. This 
minimizes threats to reliability. 
in the intervention group 
(54% of 80) than in the 
usual care group (19% of 
77) (OR, 5.4; 95% 
confidence interval [CI], 
2.2–12.9 [P<.001]). The 
Beck Depression Inventory 
score decreased 
significantly more 
(t155=2.85 [P=.005]) for 
intervention patients 
(change, −5.7; 95% CI, 
−7.6 to −3.8; df=155) than 
for usual care patients 
(change, −1.9; 95% CI, 
−3.8 to −0.1; df=155); the 
depression effect size was 
0.59 of the standard 
deviation. At the end of the 
trial, 3 intervention patients 
and 10 usual care patients 
had experienced major 
adverse cardiac events 
([P=.047]), as well as 5 
non-depressed patients 
(6%) (for the intervention 
vs non-depressed cohort, 
[P=.49]). 
with greater 
satisfaction, a 
greater reduction 
in depressive 
symptoms, and a 
promising 
improvement in 
prognosis. The 
researchers suggest 
that further trials 
of enhanced 
depression care are 
required to 
determine whether 
this type of 
treatment can 
improve post-ACS 
prognosis. 
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Wang, W., Lopez, V., 
Chow, A., Chan, S., 
Cheng, K. K. & 
He, H. (2014).  
 
A randomized controlled 
trial of the effectiveness 
of a self-help 
psychoeducation 
programme on outcomes 
of outpatients with 
coronary heart disease: 
study protocol. Journal 
of Advanced Nursing, 
70(12): 2932–2941. doi: 
10.1111/jan.12397. 
 
Randomized Controlled 
Trial with Repeated 
Measures 
 
Level I Evidence 
 
Quality Rating: B – 
Good Quality 
In this proposed 
randomized 
controlled trial, a 
convenience sample 
of 128 coronary heart 
disease outpatients 
will be recruited from 
a tertiary hospital in 
Singapore. 
Participants are 
randomly assigned to 
the 4-week 
experimental group 
and will participate in 
the program or the 
control group who 
will not participate in 
the program. The 
outcome measures 
include the: 12-item 
Short Form Health 
Survey, Perceived 
Stress Scale, Hospital 
Anxiety and 
Depression Scale and 
General Self-Efficacy 
Scale. Data will be 
collected at baseline, 
then 4 and 16 weeks 
from baseline. At the 
end, a process 
Internal Validity: As the researchers discuss, 
the best way to minimize confounding bias is 
through the use of randomization. The RCT 
proposed for this study will overcome this 
limitation and minimize threats to internal 
validity.  
 
External Validity:  There are many factors 
that could influence the results of this study 
and its generalizability, such as duration of 
illness, age and educational level.  
 
Reliability:  In the statistical point of view, 
confounding variables can be dealt with 
using multivariate repeated measure 
ANCOVA. The authors discuss that 
confounding variables will be controlled as 
covariates in the model for analysis. These 
measures will help to minimize threats to 
reliability as well as validity of the study. 
 
 
 
This RCT was proposed 
and received grant funding 
in July 2013. According to 
the researchers, nature of 
this program will benefit 
both healthcare providers 
and patients. For patients, 
this program affords them 
the flexibility to carry out 
their recovery at their own 
time. The program also 
may help patients save 
money (e.g. transportation, 
program charges) and time 
when compared with 
attending hospital-based 
rehabilitation programs. For 
the healthcare providers, 
the independent nature of 
this program will greatly 
reduce the amount of 
contact time with patients, 
which allows them to spend 
more time with patients 
who require their attention, 
for example patients with 
acute myocardial infarction. 
This will result in a more 
efficient use of health 
resources in the long run. 
Eventually, this program 
The proposed 
study is in line 
with the global 
trend in promoting 
self-management 
for chronic health 
conditions. To the 
best of research 
team’s knowledge, 
this is the first 
RCT in the region 
that incorporates a 
home-based self-
help 
psychoeducation 
approach for CHD 
patients and 
evaluates 
its effectiveness on 
patients’ outcomes, 
including HRQoL, 
psychological 
status, cardiac risk 
factors and health 
service use. The 
proposed RCT will 
make a significant 
contribution to the 
current knowledge 
of the effectiveness 
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evaluation will be 
conducted to assess 
the acceptability, 
strengths and 
weaknesses of our 
program based on the 
participants’ 
perspectives. 
aims to be available for all 
CHD patients living in the 
community. 
of home-based 
self-help programs. 
The process 
evaluation 
included in this 
study will help the 
research team 
understand the 
strengths and 
weaknesses of this 
program. If this 
home-based self-
help 
psychoeducation 
program is 
effective, it can be 
an option for CHD 
patients in addition 
to existing cardiac 
rehabilitative 
services. 
Agren, S., Berg, S., 
Svedjeholm, R., & 
Stromberg, A. (2014).  
 
Psychoeducational 
support to post cardiac 
surgery heart failure 
patients and their 
Pilot study with a 
randomized 
controlled design 
which included a 
total of 42 patient-
partner completed 
baseline assessments 
for evaluating 
psychosocial support 
Internal Validity: The 42 patient-partner 
dyads that chose to participate were 
randomized to either the experimental or 
control groups. Randomization minimizes 
threats to internal validity. 
 
External Validity: There was relatively a 
small sample of couples in this study, and 
Partners in the intervention 
group increased health in 
the role emotional and 
mental health dimensions, 
and patients increased 
health in vitality, social 
function, and mental health 
dimensions as compared 
with the control group. 
The results of this 
study suggest that 
psychoeducational 
support from a 
multidisciplinary 
team to post 
cardiac surgery 
heart failure dyads 
improves health 
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partners—A randomized 
pilot study. Intensive 
and Critical Care 
Nursing, 31: 10-18. 
doi:10.1016/j.iccn.2014.
04.005. 
 
Pilot study with a 
randomized controlled 
design. 
 
Level I Evidence 
 
Quality Rating: B – 
Good Quality 
and education from 
an interdisciplinary 
team approach. 
Patients with 
postoperative health 
failure and their 
partners were chosen 
to participate in 3 
month and 12 month 
follow up phone 
interviews. 
Randomization was 
performed using a 
random-number table 
with block of 12. 
Several 
questionnaires were 
used, including a 
demographic 
questionnaire, 
Charlson 
Comorbidity Index, 
SF-36, Beck 
Depression 
Inventory, and 
Perceived Control. 
this is a threat to external validity. There 
were some inter-group differences and 
outcomes, which would limit 
generalizability.  
 
Reliability: The researchers discussed the 
levels of significance for their results and 
placed these results in a table. The small 
sample size may have influenced that the 
difference between the groups did not reach 
statistical significance. This is a threat to 
reliability. As the researchers discuss, this 
was only a pilot study, and larger studies 
need to be undertaken. 
Patients’ perceived control 
improved significantly in 
the intervention group over 
time. 
and perceived 
control in patients 
after 3 and 12 
months. These 
results also suggest 
that interventions 
focusing on 
psychoeducational 
support can 
improve the life 
situation for the 
patient-partner and 
especially for the 
patients. 
Psychoeducational 
support appears to 
be a promising 
intervention but 
the results need to 
be confirmed in 
larger studies. 
Grace, S. L., Grewal, K., 
Arthur, H. M., 
Abramson, B. L., & 
Stewart, D. E. (2008).  
A prospective, 
controlled quasi-
experimental 157 
female cardiac 
Internal Validity: Given the nonrandom 
study design, causal conclusions about the 
changes realized for female heart patients 
Researchers found that 51 
(45.1%) of the women self-
reported participating in CR 
at 1 of 18 sites, and site-
Following a 
cardiac event, 
female patients 
improved their 
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A Prospective, 
Controlled Multisite 
Study of Psychosocial 
and Behavioral Change 
Following Women’s 
Cardiac Rehabilitation 
Participation. Journal of 
Women’s Health, 17(2): 
241-248. doi: 
10.1089/jwh.2007.0519. 
 
Prospective, Controlled 
Quasi-Experimental 
Design 
 
Level II Evidence 
 
Quality Rating: A – 
High Quality 
inpatients from three 
hospitals consented to 
participate in a 
prospective study, 
and 110 (79%) were 
retained 18 months 
post-discharge. A 
mailed survey 
discerned CR 
participation 9 
months post-
discharge. Quality of 
life (Short-Form 
Health Survey 
Physical and Mental 
Component Summary 
[SF-12 PCS and 
MCS]), exercise 
behavior (Health-
Promoting Lifestyle 
Profile II [HPLPII]), 
Exercise Benefits and 
Barriers Scale 
(EBBS), and anxiety 
and depressive 
symptoms (Hospital 
Anxiety and 
Depression Scale 
[HADS]) were 
assessed in hospital 
cannot be drawn. Non-randomization 
increases the threat to internal validity. 
 
External Validity: Generalizability is limited 
by the selection biases and differences 
between CR participants and nonparticipants. 
In particular, and as shown in other studies, 
49, 51, 52 CR participants were more likely 
to have had ACS or an ACB than a PCI and 
were better educated than nonparticipants. 
Also, because of the small number of women 
in the sample, lack of power may be masking 
changes.  
 
Reliability: The use of self-report measures 
is open to social desirability bias and other 
errors in reporting. Specifically, self-report 
of exercise behavior may be biased. The 
method through which the results were 
obtained poses a threat to reliability. 
 
verified participation was 
82.43% _ 29.97% of 
prescribed sessions. For CR 
participants, paired 
t tests assessing change 
from hospitalization to 18 
months post-discharge 
revealed significant 
improvements in physical 
quality of life (p _ 0.001), 
anxiety (p _ 0.05), and 
exercise behavior (p _ 
0.01). Women who did not 
participate in CR 
experienced significant 
improvements in physical 
quality of life (p _ 0.02), 
and depressive symptoms 
(p _ 0.03) but not exercise 
behavior. 
physical quality of 
life and affect, but 
only patients who 
participated in CR 
increased their 
exercise behavior. 
Given the cardiac 
benefits of exercise 
and that women 
are often sedentary 
and given that this 
exercise behavior 
was sustained post-
CR, these findings 
are significant. A 
sufficiently 
powered 
randomized 
controlled 
trial of women’s 
outcomes after CR 
participation is 
greatly 
needed. 
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and 18 months post-
discharge. 
McGuire, A. W., 
Ahearn, E. & Doering, 
L. V. (2015).  
 
Psychological distress 
and cardiovascular 
disease. Journal of 
Clinical Outcomes 
Management, 22(9), 
421-432. 
 
Systematic Review 
 
Level II Evidence 
 
Quality Rating: B – 
Good Quality 
Systematic Review of 
relevant and current 
(2005–2015) clinical 
trials was performed 
by a series of 
searches conducted in 
the PubMed and 
PsychINFO databases 
using Boolean 
terms/phrases along 
with manual 
extraction from the 
reference lists of 
pertinent studies. The 
researchers narrowed 
their results and 
utilized 18 relevant 
articles for this study. 
Internal Validity: All studies included were 
experimental clinical trials; however, not all 
studies utilized randomization. Non-
randomization increases the threat to internal 
validity through bias. 
 
External Validity: The researchers presented 
results from 18 studies, which is a small 
number of studies and potentially presents a 
threat to external validity. The results were 
consistent across all studies increasing the 
generalizability of the results to the general 
population.  
 
Reliability: The authors displayed their 
results of all utilized clinical trials in an 
evidence table, and discussed odds ratios 
(OR), confidence intervals (CI), and p-values 
for the trials. The significance (ORs, effect 
sizes, level of significance) of the treatment 
effects and the preciseness (CI) of the studies 
utilized limit threats to reliability.  
Screening for psychological 
distress in CVD is 
recommended. Referral and 
treatment issues need 
further exploration. 
Pharmacologic treatment of 
psychological distress in 
CVD remains equivocal; 
however, promising data 
exists for other therapies 
such as cognitive 
behavioral therapy and 
social support strategies. 
Psychological 
distress has a 
significant 
negative impact on 
patients with CVD 
and is under-
recognized by 
health care 
providers. Primary 
care providers and 
cardiovascular 
specialty providers 
are called upon to 
improve their 
recognition of 
psychological 
distress in their 
patients and assure 
referrals are made 
to collaborative 
care teams for 
proper diagnosis 
and treatment. 
Stafford, L., Hons, M. 
A., Berk, M., & Jackson, 
H. J. (2007). 
Participants were 
recruited between 
May 2005 and March 
Validity: The internal consistencies of the 
results were excellent. In terms of the 
generalizability of these findings, this study 
One hundred and ninety-
three of the recruited 
patients 
Criterion validity 
for the PHQ-9 and 
HADS was good, 
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Validity of the hospital 
anxiety and depression 
scale and patient health 
questionnaire-9 to screen 
for depression in 
patients with coronary 
artery disease. General 
Hospital Psychiatry, 
29(5): 417-424. 
doi:10.1016/j.genhospps
ych.2007.06.005 
 
Quasi-experimental 
study with post-test only 
design 
 
Level II Evidence 
 
Quality Rating: A – 
High Quality 
2006 from the 
Geelong Hospital in 
Victoria, Australia. 
All were English-
speaking patients 
who resided 
permanently in 
Australia and were 
hospitalized for 
percutaneous 
transluminal coronary 
angioplasty (PTCA), 
AMI or coronary 
artery bypass graft 
surgery (CABG) 
during this time were 
eligible for 
participation. There 
were no other 
exclusion criteria. 
Two hundred and 
twenty-nine patients 
agreed to participate 
in the study. The 
HADS and PHQ-9 
measures were 
mailed to 
participants 3 months 
post-discharge. 
included patients recently hospitalized for 
cardiac disease. It is unknown whether the 
results from this analysis would generalize to 
PHQ-9 and HADS scores among other 
populations or to patients with other 
comorbidities. 
 
Reliability: A possible limitation of this 
study is that participants were required to 
complete two measures of depression in one 
questionnaire pack. Although other measures 
were placed between these two instruments, 
and the structure and content of these two 
instruments differ, effects of repetition or 
order cannot be excluded. The use of self-
report measures is open to social desirability 
bias and other errors in reporting. 
Specifically, self-report of exercise behavior 
may be biased. The method through which 
the results were obtained poses a threat to 
reliability. 
 
(84.3%) completed both the 
structured clinical interview 
and the self-report 
questionnaires. Twenty-
eight participants did not 
return their questionnaires 
for an unknown reason, 3 
withdrew due to physical 
illness and 4 withdrew due 
to depression.  Thirty-five 
participants met diagnostic 
criteria for major 
depression (male=24; 
female=11), 13 for minor 
depression (male=10; 
female=3) and 6 for 
dysthymia (male=6; 
female=0), corresponding 
to a 3-month post-discharge 
depression rate of 28%. 
Nine (4.7%) of the 193 
participants 
met criteria for both major 
depressive disorder and 
dysthymia, so-called 
“double depression”.  The 
internal consistencies for 
the self-report 
questionnaires were 
excellent with Cronbach's α 
and both 
instruments can be 
recommended to 
identify any 
depressive disorder 
and major 
depressive disorder 
in recently 
hospitalized 
patients with CAD. 
Diagnostic 
superiority of the 
PHQ-9 over the 
HADS for major 
depressive disorder 
was reported. Both 
instruments have 
acceptable 
properties for 
detecting 
depression in 
recently 
hospitalized 
cardiac patients. 
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coefficients of 0.90 and 
0.81 for the PHQ-9 and 
HADS, respectively. The 
intercorrelation between the 
HADS and PHQ-9 was 
0.72. 
Paz-Filho, G., Licinio, 
J., & Wong, M. (2010).  
 
Pathophysiological basis 
of cardiovascular disease 
and depression: a 
chicken-and-egg 
dilemma. Revista 
Brasileira de 
Psiquiatria, 32(2): 181-
191. Retrieved from: 
http://www.ncbi.nlm.nih
.gov/pmc/articles/PMC4
259495/pdf/nihms64533
2.pdf  
 
Systematic Review 
 
Level III Evidence 
 
Quality Rating: B – 
Good Quality 
A systematic 
literature review of a 
combination of 
RCTs, quasi-
experimental studies, 
and non-experimental 
studies. The 
reviewers utilized the 
PubMed database in 
order to describe the 
pathophysiological 
link between 
cardiovascular 
disease and 
depression.   
The manuscripts 
included in the article 
were selected based 
on their 
methodological 
aspects and the 
strength of their 
findings. 
Validity: Several non-experimental studies 
were included in the review. This increases 
the threat to internal validity.  The results 
were consistent across all studies increasing 
the generalizability of the results to the 
general population. 
 
Reliability: The researchers did not include a 
specific analysis of the levels of evidence of 
the studies which they included in their 
review. This is an increased threat to 
reliability of the review. 
Depression and 
cardiovascular disease are 
both highly prevalent. 
Several studies have shown 
that the two are closely 
related. They share 
common 
pathophysiological 
etiologies or co-
morbidities, such as 
alterations in the 
hypothalamic-pituitary axis, 
cardiac rhythm 
disturbances, and 
hemorheologic, 
inflammatory and 
serotoninergic changes. 
Furthermore, antidepressant 
treatment is associated with 
worse cardiac outcomes (in 
case of tricyclics), which 
are not observed with 
selective serotonin reuptake 
inhibitors. 
There is irrefutable 
evidence that 
depression and 
CVD share 
common pathways. 
Both of these 
conditions are 
stress-reactive 
disorders of 
unknown etiology. 
To minimize 
morbidity and 
mortality, it is 
crucial to 
understand that 
MDD and CVD 
are frequently co-
morbid and that 
both conditions 
should be treated 
concomitantly, as 
the treatment of 
depression 
improves the 
patient’s quality of 
life and their 
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adherence to a 
regimen of 
medication for 
CVD. 
Sin, N. L., Yaffe, K., & 
Whooley, M. A. (2014). 
 
Depressive symptoms, 
cardiovascular disease 
severity, and functional 
status in older adults 
with coronary heart 
disease: The Heart and 
Soul Study. Journal of 
the American Geriatrics 
Society, 63: 8-15. 
doi:10.1111/jgs.13188. 
 
Prospective Cohort 
Study 
 
Level III Evidence 
 
Quality Rating: A – 
High Quality 
A prospective cohort 
study designed to 
examine how 
psychosocial factors 
influence clinical 
outcomes in 
individuals with 
coronary heart 
disease. The sample 
comprised 960 
participants. The 
severity of depressive 
symptoms was 
assessed at baseline 
and at the 5-year 
follow-up using the 
9-itme Patient Health 
Questionnaire (PHQ). 
Cardiovascular 
severity assessments 
were obtained at 
baseline and again at 
5 years. 
Internal Validity: There was a well-defined 
and representative sample of patients at 
similar points of cardiovascular severity. 
Follow-up was sufficiently long and 
complete at the end of the 5-year period. 
These factors minimize threats to internal 
validity. 
 
External Validity:  It is unknown whether the 
findings may be generalized to older 
populations, such as those aged 75 and older, 
since the average of patients was 67. The 
sample was also largely male, and many 
were veterans, although other characteristics 
of the sample were representative of 
individuals with CHD, including ethnic 
diversity (40% were nonwhite) and a wide 
range of diagnoses. These factors pose 
threats to external validity. Also, a number of 
confounding variables may have been 
responsible for the association between 
depressive symptoms and functional decline, 
although demographic characteristics, BMI, 
comorbid conditions, and health behaviors 
were adjusted for, suggesting that these 
variables did not explain the relationship 
Over 5 years, the 
researchers found higher 
baseline depressive 
symptoms predicted greater 
risk of functional decline, 
whereas higher baseline 
exercise capacity was 
associated with lower risk 
of functional decline. In 
658 of the participants, 5-
year changes in depressive 
symptoms and exercise 
capacity were associated 
with 5-year changes in 
functional status as well. 
In older adults 
with coronary 
heart disease, 
depressive 
symptoms and 
lower exercise 
capacity predicted 
functional decline 
over 5 years. In 
contrast, other 
traditional 
measures of 
cardiovascular 
severity such as 
angina pectoris 
were not 
independently 
predictive of 
subsequent 
functional status. 
These results 
suggest that efforts 
to treat and 
decrease 
depressive 
symptoms may be 
as important as 
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between depressive symptoms and functional 
status. The researchers attempted to adjust 
for important confounding variables, but list 
this as a threat to external validity and a 
limitation of the study.  
 
Reliability:  The researchers discuss the 
magnitude of the relationship between 
predictors (RR) and the preciseness of the 
study estimates (CI), which minimize threats 
to reliability. As the researchers discuss, it is 
unknown whether the results would differ if 
more-frequently assessed, short-term 
relationships, such as associations between 
changes in angina pectoris and functional 
status every 6 months, were examined. This 
poses a threat to the reliability of the results. 
treating actual 
symptoms of 
cardiovascular 
disease to enhance 
functional status. 
Eurelings, L. S. M., 
Ligthart, S. A., van 
Dalen, J. W., van 
Charante, E. P., van 
Gool, w. A., & Richard, 
E. (2013).  
 
Apathy is an 
independent risk factor 
for incident 
cardiovascular disease in 
A prospective cohort 
study of 1810 
community-dwelling 
older individuals 
(70–78 years of age) 
without a history of 
CVD or stroke. 
Symptoms of apathy 
and depression were 
assessed with the 15-
item Geriatric 
Depression Scale. 
Internal Validity:  There was a well-defined 
and representative sample of patients at 
similar points of cardiovascular severity. 
Follow-up was sufficiently long and 
complete at the 2-year follow-up. These 
factors minimize threats to internal validity. 
 
External Validity: The large sample size of 
1,810 older individuals minimizes threats to 
external validity, and the results are easily 
generalizable to patients within the included 
Symptoms of apathy and 
depression were present in 
281 (15.5%) and 266 
(14.7%) participants, 
respectively. Incident CVD 
occurred in 62 (3.5%) 
participants and stroke in 
55 (3.1%) participants. 
Apathy was associated with 
incident CVD after 
adjustment for 
demographics and 
Symptoms of 
apathy in older 
persons without a 
history of 
cardiovascular 
disease or stroke 
are highly 
prevalent and are 
strongly associated 
with incident 
cardiovascular 
disease. This 
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the older individual: a 
population-based cohort 
study. International 
Journal of Geriatric 
Psychiatry, 29: 454-463. 
 
Prospective Cohort 
Study 
 
Level III Evidence 
 
Quality Rating: A – 
High Quality 
Incident CVD and 
stroke were assessed 
after 2 years follow-
up. The associations 
of symptoms of 
apathy and 
depression with 
incident CVD and 
stroke were analyzed 
separately using 
logistic regression 
analysis. 
age group. The researchers also adjusted for 
confounding variables, which limits threats 
to external validity. 
 
Reliability: The researchers discussed odds 
ratios (OR), confidence intervals (CI), and 
levels of significance for their findings. They 
discussed the treatment effect and 
preciseness of the intervention. This 
minimizes threats to reliability. 
cardiovascular risk factors 
(odds ratio (OR) = 2.60, 
95% CI = 1.46–4.65). 
Exclusion of subjects with 
depressive symptoms 
yielded a similar OR (2.94, 
95% CI = 1.45–5.96, n = 
1544). 
association is 
independent from 
well-established 
cardiovascular risk 
factors and from 
the presence of 
depressive 
symptoms. 
Therefore, apathy 
can be considered 
as an important 
risk factor for 
incipient 
cardiovascular 
disease. Since the 
nature of these 
symptoms may 
lead to a tendency 
to withdraw from 
clinical care, this 
emphasizes the 
need for 
recognition of 
apathy symptoms 
in older persons 
without previous 
cardiovascular 
disease or stroke. 
Van der Kooy, K., van 
Hout, H., Marwijk, H., 
Meta-analyses and 
meta-regression 
Internal Validity:  The methodological 
quality of every study utilized for this review 
After inclusion and 
exclusion criteria, 28 
The results of this 
elaborate 
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Marten, H., Stehouwer, 
C., & Beekman, A. 
(2007).  
 
Depression and the risk 
for cardiovascular 
diseases: systematic 
review and meta 
analysis. International 
Journal of Geriatric 
Psychiatry, 22: 613-626. 
doi: 10.1002/gps.1723 
 
Systematic Review and 
Meta-Analysis of Non-
Experimental Studies 
 
Level III Evidence 
 
Quality Rating: A – 
High Quality 
 
analyses of 
longitudinal cohort 
and case-control 
studies reporting 
depression at baseline 
and CVD outcomes 
at follow-up. The 
following databases 
were utilized in this 
project: Medline 
(1966–2005) and 
PSYCHINFO (1966–
2005). The following 
search terms were 
used: depression, 
depressive disorder, 
depressi* (truncated), 
cardiovascular 
diseases, myocardial 
ischemia, coronary, 
infarct* (truncated), 
ischemic, heart 
diseases. 
was independently assessed by two of four 
reviewers, who were blinded for author and 
journal. Researchers used a standardized 
checklist of predefined quality criteria for 
prognostic cohort and case-control studies, 
based on the checklist. The checklist 
comprised 18 items concerning internal 
validity, generalizability, and precision, 
which could be scored as positive, negative 
and 
unclear. These methods should minimize 
threats to validity and reliability. The 
researchers only included published studies 
and left out unpublished studies. This 
presents an issue of publication bias which is 
a threat to validity.  
 
External Validity: There were 28 studies 
contained in this study. Of these the 
researchers felt that 11 studies were high 
quality evidence.   
 
Reliability: The authors displayed their 
results of all utilized studies in an evidence 
table, and discussed odds ratios (OR), 
confidence intervals (CI), and p-values for 
the trials. The significance (ORs, effect sizes, 
level of significance) of the treatment effects 
articles were chosen. The 
risk of depression for CVD 
onset was higher in 
populations that were free 
of CVD at baseline. 
systematic meta-
analysis and meta-
regression analysis 
confirm that 
depression is 
associated with the 
development of 
various CVDs in 
community-
dwelling and 
general practice 
populations. 
Depressed mood 
moderately 
increased the risk 
for MI, CHD, 
cerebrovascular 
diseases and other 
CVDs to the same 
level (1.43–1.63). 
Only the combined 
risk of the MI-
studies, the group 
with the strictest 
IC-10 definition, 
did not suffer from 
heterogeneity. 
There was a great 
methodological 
variation among 
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and the preciseness (CI) of the studies 
utilized limit threats to reliability. 
the selected 
studies. 
Hare, D. L., Toukhsati, 
S. R., Johansson, P. & 
Jaarsma, T. (2014). 
 
Depression and 
cardiovascular disease: 
A clinical review. 
European Heart 
Journal, 35: 1365-1372. 
Retrieved from: 
http://eurheartj.oxfordjo
urnals.org/content/ehj/35
/21/1365.full.pdf 
 
Systematic Clinical 
Review of experimental 
studies 
 
Level III Evidence 
 
Quality Rating: B – 
Good Quality 
 
Clinical review of 
five major 
randomized 
controlled trials to 
evaluate the effects of 
anti-depressant 
pharmacotherapy on 
depression in 
cardiovascular 
disease settings. 
Validity: A total of five randomized control 
trials were reviewed. The researchers felt that 
these were all high quality evidence. The five 
trials included significant numbers of 
patients ranging from 101 to 2,481. 
However, the low number of studies 
included limits the validity of the review.  
 
Reliability: The authors clearly displayed the 
results of all utilized studies in an evidence 
table, and this limits threats to reliability.  
Cardiovascular disease is 
the leading cause of death, 
disability, and disease 
burden in the developed 
world. Depression is 
common in CVD patients 
and is linked to higher 
mortality and morbidity 
rates. An American Heart 
Association Science 
Advisory suggested that the 
PHQ screening tools appear 
to be the most useful in this 
population of patients. 
There is sufficient 
evidence to 
support the 
introduction of 
exercise, talking 
therapies, and anti-
depressant 
medications to 
reduce depression 
in CVD patients. 
Although research 
has yet to clearly 
and consistently 
identify 
cardiovascular 
benefits in this 
regard, depression 
is a fundamental 
determinant of 
quality of life in 
these patients. 
Many questions 
remain, and further 
research is clearly 
required to unravel 
potential 
pathophysiological 
mechanisms and 
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 to determine both 
the best 
management 
strategies and the 
effects on clinical 
outcomes. 
Lichtman, J. H., Bigger, 
J. T., Blumenthal, J. A., 
Frasure-Smith, N., 
Kaufmann, P. G., 
Lespérance, F.,  
…Froelicher, E. S. 
(2008).  
 
Depression and coronary 
heart disease 
recommendations for 
screening, referral, and 
treatment: A science 
advisory from the 
American Heart 
Association Prevention 
Committee of the 
Council on 
Cardiovascular Nursing, 
Council on Clinical 
Cardiology, Council on 
This is a 
multispecialty 
consensus document 
which provides 
experts’ opinions and 
reviews of the 
evidence linking 
depression with CHD 
and provides 
recommendations for 
healthcare providers 
for the assessment, 
referral, and 
treatment of 
depression. A group 
of experts reviewed 
60 prospective 
studies and 100 
narrative reviews on 
which they based 
their conclusions and 
recommendations for 
healthcare providers. 
Internal Validity: The researchers discuss 
several non-experimental studies, and this 
increases threats to internal validity.  
 
External Validity: Despite differences in 
sample sizes, duration of follow-up, and 
assessment of depression and depressive 
symptoms, these studies included in the 
experts’ review have demonstrated relatively 
consistent results. This minimizes threats to 
validity and increases generalizability.   
 
Reliability: The researchers reviewed a large 
number of articles, and this adds to the 
reliability of their conclusions and 
recommendations. 
The following 
recommendations were 
made by the American 
Heart Association:  
At a minimum, the Patient 
Health Questionnaire 
(PHQ-2) provides 2 
questions that are 
recommended for 
identifying currently 
depressed patients. If the 
answer is “yes” to either or 
both questions, it is 
recommended that all 9 
PHQ items (PHQ-9) be 
asked. For patients with 
mild symptoms, follow-up 
during a subsequent visit is 
advised. In patients with 
high depression scores, a 
physician or nurse should 
review the answers with the 
patient. There is no 
evidence that treatments for 
The high 
prevalence of 
depression in 
patients with CHD 
supports a strategy 
of increased 
awareness and 
screening for 
depression in 
patients with CHD. 
Specifically, 
routine screening 
for depression in 
patients with CHD 
in a variety of 
healthcare settings 
and coordination 
of care among 
healthcare 
providers. 
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  Note: Evidence ratings (Level I-IV) and Quality ratings for the literature are based on Dearholt & Dang’s (2012) book John Hopkins 
Nursing   Evidence-Based Practice: Model and Guidelines.
Epidemiology and 
Prevention, and 
Interdisciplinary Council 
on Quality of Care and 
Outcomes Research. 
Circulation, 118: 1768-
1775. doi: 
10.1161/circulationAHA
.108.190769 
 
Clinical Practice 
Guidelines 
 
Level IV Evidence 
 
Quality Rating: A – 
High Quality 
depression are differentially 
effective in cardiac versus 
other patients. 
Evidence also suggests that 
depressed patients who are 
not responsive to treatment 
for depression may be at 
greater risk for adverse 
cardiac events. Aggressive 
cardiologic care may help 
mitigate this increased risk. 
Depressed patients may 
also require additional 
clinical management to 
ensure compliance with 
cardiac treatment regimens 
and to promote lifestyle 
behavior change. 
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Appendix B: Evidence Level and Quality Guide 
Evidence Levels  Quality Guides 
Level I – Experimental studies, Randomized 
Control Trials (RCT), Systematic Reviews of 
RCTs with or without meta-analysis 
A High Quality: Consistent, generalizable results; 
sufficient sample for the study design; adequate 
control; definitive conclusions; consistent 
recommendations based on comprehensive 
literature review that includes thorough reference 
to scientific evidence. 
B Good Quality: Reasonably consistent results; 
sufficient sample for the study design; some 
control, fairly definitive conclusions; reasonably 
consistent recommendations based on fairly 
comprehensive literature review that includes 
some reference to scientific evidence. 
C Low Quality or Major Flaws: Little evidence 
with inconsistent results; insufficient sample size 
for study design; conclusions cannot be drawn.   
Level II – Quasi-experimental studies, Systematic 
Reviews of a combination of RCTs and quasi-
experimental studies, or quasi- experimental 
studies only, with or without meta-analysis 
Level III – Non-experimental studies, Systematic 
Reviews of a combination of RCTs, quasi-
experimental studies, and non-experimental 
studies, or non-experimental studies only, with or 
without meta-analysis 
Qualitative studies or Systematic Reviews with or 
without meta-synthesis 
Level IV – Opinions of expected authorities and/or 
nationally recognized expert committees/consensus 
panels based on scientific evidence 
Includes: Clinical Practice Guidelines and 
Consensus Panels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Deaholt & Dang, 2012). 
A High Quality: Material officially sponsored by 
professional, public, private, organization, or 
government agency; documentation of a 
systematic literature search strategy; consistent 
results with sufficient numbers of well-designed 
studies; criteria-based evaluation of overall 
scientific strength and quality of included studies 
and definitive conclusions; national expertise is 
clearly evident; developed or revised within the 
last 5 years. 
B Good Quality: Material officially sponsored by 
professional, public, private, organization, or 
government agency; reasonably thorough and 
appropriate systematic literature search strategy; 
reasonably consistent results; sufficient numbers 
of well-designed studies; evaluation of strengths 
and limitations of included studies with fairly 
definitive conclusions; national expertise is clearly 
evident; developed or revised within the last 5 
years. 
C Low Quality or Major Flaws: Material not 
sponsored by official organization or agency; 
undefined, poorly defined, or limited literature 
search strategy; no evaluation of strengths or 
limitations of included studies, insufficient 
evidence with inconsistent results, conclusions 
cannot be drawn; not revised within the last 5 
years.  
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Appendix C: Patient Health Questionnaire Depression Screening Tool
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Appendix D 
 
Stetler’s Model of Evidence-Based Practice 
 
 
